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“.…¡Moito sabés, miña vella, 
moito de sabiduría! 
¡Quen poidera correr mundo 
por ser como vós sabida! 
Que anque traballos se pasen 
aló polas lonxes vilas, 
tamén ¡que cousas se saben!, 
tamén ¡que cousas se miran!… 
 
…Amén, miña vella, amén; 
mais, polas almas benditas, 
hoxe dormirés nun leito 
feito de palliña triga, 
xunta do lar que vos quente 
ca borralliña encendida, 
e comerés un caldiño 
con patacas e nabiza. ….” 
 
Rosalia de Castro, 1863 
 
 
 
 
A mi abuela Estrella  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
Index of contents: 
 
1. Introduction  and aim of the study……………………………………………….    7 
2. Material and methods: 
2.1. Animals …………………………………………………………….… 14 
2.2. Donors………………………………………………………………… 15 
2.3. Design of the groups…………………………………………………... 15 
2.4. Anaesthesia and surgical procedure….……………………………….. 16 
2.5. Preparation of  human blood ………..………………………………… 18 
2.6. Perfusion system ……………………………………………………… 18 
2.7. Intravital microscopy (IVM)………………………………………..     19 
2.8. Blood samples. Blood parameters   ………………………………….   20 
2.9. Smears ……………………………………………………………….   21 
2.10. Cyto-immunological monitoring……………………………………    22 
2.11. Biopsies…………………………………………………………….     23 
2.12. Histological and immunohistochemical techniques…………………   24 
2.13. Histological evaluation………………………………………………   28 
2.14. Statistical analysis…………………………………………………    30 
 
3. Results: 
3.1. Haematological parameters 
3.1.1. White Blood Cells…………………………………   32 
3.1.2. Red Blood Cells …………………………………...  35 
3.1.3. Platelets ……..…………………………………….   39 
3.1.4. Haematocrit ……..…………………………………. 42 
3.1.5. Haemoglobin …….………………………………… 45 
 
3.2. Cytological parameters 
3.2.1. Lymphocytes………………………………………  49 
3.2.2. Neutrophils………………………………………     52 
3.2.3. Monocytes…………………………………………   55 
3.2.4. Microphotographs…………………………………   58 
 
 5
3.3. Cyto-immunological monitoring 
3.3.1. Lymphocytes……………………………………… 63 
3.3.2. Neutrophils……………………………………….   67 
3.3.3. Monocytes………………………………………...  70 
3.3.4. Microphotographs…………………………………  73 
 
3.4. Histology and immunohistochemistry 
3.4.1. Results……………………………………………   78 
3.4.2. Haematoxylin/Eosin………………………………   85 
3.4.3. CD45 and Granulocyte Esterase………………….   93 
3.4.4. CD31, Masson’s Thrichrome, Weiger`s 
Haematoxylin………………………………. ……   101 
3.4.5. IL-4……………………………………………….   109 
 
4. Discussion: 
4.1. Material and methods 
4.1.1. IRI and transplantation…………………………… 111 
4.1.2. Polyclonal antibodies…………………………….. 112 
4.1.3. The animal model………………………….. ……. 114 
4.1.4. Evaluation of the results………………………….. 115 
 
4.2. Results 
4.2.1. Influence of ATGs on peripheral blood counts……. 118 
4.2.2. Influence of ATGs on peripheral blood smears…..... 120 
4.2.3. Influence of ATGs on WBC subpopulations………. 121 
4.2.4. Influence of ATGs on tissue, vascular damage and 
leukocyte infiltration………………………………   123 
5. Summary and conclusions…………………………………………………………… 125 
6. Zusammenfassung……………………………………………………………………  127 
7. Appendix……………………………………………………………………………..  129 
8. Literature……………………………………………………………………………..  141 
9. Acknowledgements…………………………………………………………………..  163 
10. C.V. ………………………………………………………………………………….  165 
 6
Abbreviations: 
 
• IRI:               Ischemia-Reperfusion Injury  
• OFR:    Oxygen-free Radicals 
• ATG:          Antithymocyte Globulin 
• ALS:            Antileukocyte sera  
• MHC:           Major Histocompatibility Complex 
• HLA:          Human Leukocyte Antigen 
• ADCC:         Antibody-dependant Cellular Cytotoxicity 
• ISR:    Institute for Surgical Research 
• WBC:           White Blood Cells 
• RBC:             Red Blood Cells 
• Plat:              Platelets 
• Hct:              Haematocrit 
• Hb:    Haemoglobin    
• EC:    Endothelial Cells    
• TNF-α :   Tumor Necrosis Factor-alpha  
• ICAM-1:   Intercellular Adhesion Molecule-1    
• VCAM:   Vascular Adhesion Molecule  
• CD:    Cluster of Differentiation 
• LCA:    Leukocyte Common Antigen 
• IL:    Interleukin 
• CIM:    Cyto-Immunological Monitoring 
• PMN:    Polymorphonuclear 
• PECAM:   Platelet Endothelial Cell Adhesion Molecule 
• IVM:    Intravital Microscopy 
• H/E:    Haematoxylin-Eosin 
• ANOVA:   Analysis of Variance  
• PBS:    Phosphate-buffered Saline  
• SI:    Short Ischemia 
• LI:    Long Ischemia 
• PB:     Peripheral Blood 
• LGL:    Large Granular Lymphocyte 
• GE:    Granulocyte Esterase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 7
1. INTRODUCTION 
 
 
Depriving a tissue of its blood supply leads to a severe cellular dysfunction and ultimately cell 
death, resulting in serious consequences for the tissues and the whole organism (58). Ischemia-
reperfusion injury (IRI) is a vital problem in organ transplantation as no organ can be 
transplanted without suffering from ischemia and posterior reperfusion injury (72, 100). IRI 
constitutes an acute inflammatory process by which cells or organs are damaged first by 
temporary ischemia, hypoxia and accumulation of toxic metabolites and later by reperfusion due 
to cell activation (118). This process involves cell surface adhesion molecule expression (99), 
which is crucial for the recruitment and infiltration of effector cells in the reperfused tissue (14, 
10, 69, 146). These mechanisms are also involved in the rejection process of transplanted solid 
organs (5, 66, 71). Activation of endothelial cells (EC) and white blood cells (WBC), in 
particular neutrophils, is one of the main underlying mechanisms in IRI (185, 195).  
IRI is strongly associated with the localisation of neutrophils in the ischemic regions, which 
occurs within the initial hours of reperfusion. After implantation of an allograft, host blood 
perfuses the donor organ, triggering a cascade of receptor ligand interactions (51, 73) responsible 
for endothelial damage and cell activation (151). Emigration of neutrophils is evident both by 
histological (4, 133) and cytological methods (200). Presence of neutrophils in the tissue due to 
reperfusion causes injury beyond the ischemic aggression, as interventions against adhesion 
properties of neutrophils and leukotactic activity have significantly reduced the amount of 
damaged tissue (83, 103, 104, 113-115, 203). 
IRI is also associated with the production of oxygen-derived free radicals (OFR), that cause cell 
membrane damage as well as oedema and have a very important role in activating the 
complement cascade (109), resulting in the rapid expression of the adhesion molecules on the 
endothelial cell surface, thus enhancing the reperfusion injury (86, 122). OFR include the 
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superoxide anion and the hydroxyl ion. OFR can be cytotoxic to cellular components as a result 
of degradation of proteins and nucleic acids and lipid peroxidation of membranes and may not be 
controlled by endogenous anti-oxidative mechanisms such as superoxide dismutase (135). 
At the time of reperfusion, the EC surface becomes a site of intense interaction between different 
types of leukocytes and their adhesion molecules, leading to intermediate adhesion (rolling) 
through the action of selectins and to permanent adhesion of the leukocytes to the EC (sticking) 
triggered by integrins. Different molecules including tumor necrosis factor-alpha (TNF-α), 
intercellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule (VCAM) rapidly 
undergo conformational changes that increase their avidity for endothelial ligands for both 
lymphocytes (ß2 integrin leukocyte function associated antigen) and neutrophils (ß1 integrin 
very late antigen-4) (27, 65, 116). These interactions between oxygen radicals, adhesion 
molecules, activated WBC and EC may represent the key step in the process of intragraft antigen 
recognition by allowing the lymphocytes and the neutrophils to migrate into the graft, initiating 
or developing processes which lead to allograft destruction (101, 168). Transendothelial 
migration of WBC, especially lymphocytes and neutrophils, are also stimulated by means of 
local endothelial chemokine activation (112). 
Long-term outcome of the graft may also be influenced by IRI and subsequent acute rejection 
episodes related to endothelial and vascular damage (169). Organs that are used for 
transplantation undergo varying periods of cold ischemia. Long periods of cold storage result in 
an increased susceptibility to damage upon reperfusion (95). For this reason organ preservation is 
fundamental for the outcome of transplanted organs.  
To summarise, it is evident that immunological interactions leading to activation of different 
WBC subsets play an essential role in IRI and later outcome of graft survival, so that 
immunosuppression becomes a vital tool to prevent and treat these phenomena.  
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During vertebrate evolution the immune system has evolved in such a way that it is able to 
distinguish self from nonself. The necessity for such an advanced antigen recognition system lies 
on the fact that an infected host first needs to identify pathogens before it can initiate their 
elimination. During ontogenesis the immune system is educated to avoid reacting against self 
structures (autoantigens). This process of eliminating or controlling self reactivity does not 
always reach the level of perfection as is reflected by the existence of a large number of 
autoimmune disorders. In these types of diseases, immunocompetent cells or their products 
mount pathological reactions towards autoantigens. Susceptibility or resistance develop many 
types of autoimmune diseases controlled by multiple genetic components. Candidates are the 
polymorphic gene products of the major histocompatibility complex (MHC) and those of the T-
cell-receptor system which are involved in the initial steps of immune recognition (163). In 
addition, activated T-cells and many other immunocompetent cells have the capacity to secrete a 
large variety of cytokines. These so-called biological response modifiers play a key role in the 
immune system since they control the potential to augment or diminish the strength of 
immunological responses. At the other end of the spectrum of immune regulation, one finds the 
problems that clinicians face in bone marrow and solid organ transplantation. The recipient's 
immune system may recognize structures on foreign tissues (alloantigens) resulting in the 
rejection of the graft. Especially the gene products of the MHC are known to act as major 
barriers for successful transplantation. Besides immunosuppressive protocols, matching of MHC 
alleles between donor and recipient is known to have beneficial effects on graft survival. 
The crucial role of immunological mechanisms in the rejection of grafts was first demonstrated 
by Medawar (120) in 1944, who discovered important characteristics of this process, such as 
latency or memory induction. The involvement of cellular and humoral mechanisms in the 
immune response was described by Mitchinson in 1954 (128). Essential investigations in the 
field, e.g., the HLA-system or the differentiation of T- and B- cells were carried out in the 60´s 
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(37, 56, 126, 163). At the same time the first immunosuppressive drugs, corticosteroids, were 
developed. 
The initial experiments performed with cytotoxic agents such as benzene, toluene or irradiation 
were interrupted due to the undesirable side-effects and high rates of morbidity and mortality 
(181). Non-selective antiproliferative agents such as Cyclophosphamide, Azathioprine and 
Micophenolic acid analogues were used, alone or in combination with steroid therapy (15, 62, 
87, 153, 173). This resulted in an improvement of the transplant outcome while it maintained 
considerable harm to the patients due to their toxicity (150). Drugs that inhibit cytokine synthesis 
such as Cyclosporine A, Tacrolimus or cytokine receptor binding monoclonal antibodies such as 
anti-CD25 as well as inhibitors of signal transduction like Syrolimus improved the 
immunosuppressive therapy by prolonging the graft survival (141), diminishing the acute 
rejection episodes and permitting the reduction of steroids (150) in the therapy with the 
subsequent diminution of the side-effects. However, they show a high nephrotoxicity in 
combination therapies and other undesirable adverse events such as hypertension, neurotoxicity 
and hyperlipidaemia (141). 
Specific molecules against EC ligands, T-cell receptors or G-protein-ligand are used still 
experimentally and although the results are very promising they are not used in clinical protocols 
at the moment (2, 127).  
Despite these latest improvements of immunosuppressive agents the IRI paradigm is still a main 
obstacle in organ transplantation, vascular damage and graft rejection as most of the 
immunosuppressive agents are specific for one action yet not covering the whole spectrum of 
possible endothelial-molecular-cellular interactions. 
There is, however, a group of drugs named generally polyclonal antilymphocyte preparations, 
which may alleviate the ischemia/reperfusion paradigm, as they show a modulatory effect in the 
immune system not only against the cellular mechanisms but also against the humoral 
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mechanisms, including adhesion molecules (33, 187). This thesis will focus on the action of 
antithymocyte globulins (ATG) upon ischemia-reperfusion injury.  
Antileukocyte sera (ALS) were first described in 1899 by Metchnikoff. He proposed that 
xenoantibodies coat foreign cells, leading to their destruction (124, 125), a proposal that led to 
the application of animal antihuman polyclonal antibodies to reduce rejection reactions in 
clinical practice decades after. Several species were investigated to see which one would be the 
best source of ALS for its application on human beings. Horse would be “a priori” the best 
source due to the large quantity of product available in an individual animal. However, the 
efficacy of horse antibodies varies considerably. Sheep and goats were also dismissed due to 
their unreliability. Rabbits were identified as the best antibody producers despite the small 
quantity of serum available per animal. The antibodies present in these sera were generally 
named antilymphocyte, i.e., thymocyte globulins. 
These antibodies bind to cell surface receptors, thereby opsonizing lymphocytes for complement-
mediated lysis or reticuloendothelial cell-dependant phagocytosis. ATGs recognise most of the 
molecules involved in the T-cell activation cascade such as CD2, CD3, CD4, CD8, CD11a, 
CD18, CD25, HLA DR and HLA class I (24). Although lymphocyte depletion constitutes the 
primary mechanism of the immunosuppressive effects of ATG, other mechanisms such as 
blocking of adhesion molecules and apoptosis induction are involved. 
As explained above, depletion and modulation of peripheral blood B- and T-cells is the main 
effect of ATG (129, 166, 183, 211). T-cell depletion involves active cell death, demonstrated by 
annexin V binding (41) and TUNEL analysis (157). Maximal depletion occurred in blood by 
means of a complement-dependent lysis. A second mechanism of T-cell depletion would be an 
activation-associated apoptosis, Fas- and TNF-independent (52, 53). Profound 
immunosuppression is evidenced by a peripheral blood T-cell lymphocyte count of less than 150 
T-cells/ml (88). Monitoring of the lymphocyte subsets (CD2, CD3, CD4, CD5, CD7, CD8, 
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CD14, CD19 and CD25) confirmed the broad range of T-cell specifities of ATGs (1, 55, 160, 
190). Over 85% depletion was shown after the first two weeks of treatment for CD2, CD3, CD4, 
CD8, CD25, CD56 and CD57 lymphocytes while monocytes underwent less marked depletion 
and B-cells were almost unaffected (19). ATGs present also functional effects on preactivated T-
cells, which may be relevant in their activity on acute cellular rejection. ATG induces Fas-
Ligand (Fas-L) (CD95L) and TNFα expression on resting T cells (22). OKT3 shares this 
property although it is more active on preactivated than on resting T cells (7). Induction of Fas-L 
expression on resting cells is completely inhibited by Cyclosporine, decreased by corticosteroids 
but only marginally affected by Rapamycin. Preactivated T-cell blasts as well as NK-cells may 
also be attacked by ATGs by a mechanism of Antibody-Dependant Cellular Cytotoxicity 
(ADCC) (134). 
In addition to depletion and apoptosis induction, some major functional effects are also achieved 
by ATGs such as modulation of leukocyte surface antigens (23) and blocking of adhesion 
molecules (20), both being relevant to transplantation. 
Modulation by ATG applies to molecules that control T-cell activation (T-cell receptors CD2, 
CD3, CD4, CD5, CD6, CD8) and also to molecules involved in leukocyte endothelium 
interaction such as the ß2 integrins, especially LFA1 (CD11a). Even low concentrations of ATG 
induce a nearly complete disappearance of LFA1 on monocytes, granulocytes and lymphocytes 
(91). 
Blocking of adhesion molecules at high dosage is another property of ATGs. Important 
lymphocyte activation molecules such as ß1 and ß2 integrins and even endothelial inflammatory 
molecules such as ICAM1 are efficiently blocked by ATG (23). This property may reduce one of 
the most important features of IRI, the deleterious effects of reperfusion in the microvasculature 
of tissues and solid organs.  
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These properties have also an outstanding clinical relevance. ATGs are included in many clinical 
protocols as pre-induction therapy and post-transplantation therapy (12, 31, 78, 102) in spite of 
their side effects (85, 111, 131, 171). These unique properties of ATG preparations, not achieved 
by other immunosuppressive agents, make ATG an interesting subject of study as lymphocyte 
antigens and adhesion molecules play a crucial role in IRI. 
 
AIM OF THE STUDY 
 
Among others, IRI is a major problem in organ transplantation. Polyclonal ATGs are able to 
block the main cellular features of IRI, including cell activation and release of inflammatory and 
adhesion molecules. At the time, three different polyclonal ATGs from three companies are 
available. These drugs do not have a common origin and therefore may possess different 
molecular and clinical properties. All of them have been raised in rabbits although from different 
antigens. ATG-Fresenius (S) ® (Fresenius GmbH, Bad Homburg, Germany) is serum from 
rabbits which have been immunized with the Jurkat cell line while Thymoglobuline® (Imtix-
SangStat, California, USA) and Tecelac® (Biotest GmbH, Dreieich, Germany) are developed 
from rabbit immunization with human thymocytes. Our objective was to test the influence of 
these three different pATGs on ischemia/reperfusion injury in a non-human primate model as 
well as to compare their activity. To study the influence of ATGs on IRI, the following 
parameters were evaluated: 
• WBC subpopulations 
• Influence on blood parameters 
• WBC activation and co-activation 
• Tissue infiltration and damage 
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2. MATERIAL AND METHODS 
 
2.1. Animals 
This study was approved by the Bavarian government (N° AZ-211-2531-33/2000). The animals 
in which our experiments were performed were monkeys, from two different species, 
cynomolgus monkeys (Macacca fascicularis) and baboons (Papio hamadryas). The distribution 
in gender and age between the different monkeys as well as the body weights are given in the 
table 1. 
14 cynomolgus monkeys (Macacca fascicularis) and 5 baboons (Papio hamadryas) were 
purchased from two different centres (DPZ 1, ZVM2) and housed in the husbandry of the Institute 
for Surgical Research (ISR) for two days prior to the experiments. Animals were feed with fresh 
fruit, vegetables and pellets3. The animals were handled according to the directives from ISR and 
the local Bavarian government. 
The animals were assigned to four groups according to the ATG used for the perfusion 
experiments. The blood of all monkeys was of blood group 0. 
 
 
 
 
 
   Table 1: Distribution of the animals according to species, sex, age and weight. 
    
 
                                                 
1 Deutsches Primatenzentrum , 37077 Göttingen, Germany 
2 Zentrale Versuchstierhaltung der Innenstadt. Klinikum LMU, München, Germany 
3 ssniff Mü Z©; ssniff Versuchstier-Diäten GmbH, Soest, Germany 
Species Number Male Female Age (months) Weight (Kg) 
Cynomolgus 14 8 6 52,57 + 35,84 4,02 + 0,85 
Baboon 5 3 2 47 + 27,29 5,38 + 3,58 
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Species Biotest Fresenius Merieux Control 
Cynomolgus 4 3 4 3 
Baboon 2 1 1 1 
      
     Table 2: Distribution of the animals according to ATG 
 
2.2. Donors 
300 ml of blood were taken from 19 different volunteers 1 hour prior to the begin of the 
reperfusion. Both male and female donors were accepted. In some cases a second donation was 
needed and obtained from a different donor. All donors were free from chronic or acute diseases. 
The blood was collected with a butterfly catheter4 and stored in 50 ml syringes5  previously 
rinsed with heparin6 in an incubator maintaining a constant temperature of 37°C. The blood of all 
donors was of blood group 0.  
 
2.3. Design of the Groups 
Isolated limbs of the animals were considered as single experiments except those in which 
perfusion was not possible due to technical reasons. The limbs were classified into eight different 
groups according to the ATG present in the perfusing blood and the length of the ischemia time. 
The polyclonal ATGs employed were: 
• Tecelac ®, ATG-Biotest, Biotest GmbH, Germany 
• ATG-Fresenius (S)®, Fresenius kabi GmbH, Bad Homburg, Germany 
• Thymoglobuline®, ATG-Merieux, Imtix-SangStat, California USA 
 
 
                                                 
4 LEM 21 G-0,80© pfm Produkte für die Medizin; 50996 Köln, Germany 
5 Braun Injekt 50ml B.Braun Melsungen AG, 34209 Melsungen, Germany 
6 Heparin-Natrium Braun 25000 i.e. B.Braun Melsungen AG , Melsungen, Germany 
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The ischemia times ranged from: 
• Short Ischemia (SI): 60 + 10 minutes 
• Long Ischemia (LI): 120 + 10 minutes 
 
 A total of 60 single experiments was performed and divided into groups named according to the 
ATG used and the ischemia time as follows: 
Group Abbreviation Number of experiments 
Biotest Short Ischemia BSI 11 
Fresenius Short Ischemia FSI 7 
Merieux Short Ischemia MSI 7 
Control Short Ischemia CSI 9 
Biotest Long Ischemia BLI 9 
Fresenius Long Ischemia FLI 5 
Merieux Long Ischemia MLI 4 
Control Long Ischemia CLI 8 
 
Table 3: Design of the experimental groups. 
 
2.4. Anaesthesia and surgical procedure 
The animals were pre-medicated by an intramuscular (i.m.) injection of 15 mg/kg of Ketamine7, 
2 mg/kg of Xylazine8 and 0,1 mg/kg Atropine9. After 10-20 minutes the animals were intubated 
                                                 
7 Ketavet© Pharmacia & Upjohn GmbH 91058 Erlangen, Germany 
8 Rompun© BayerVital GmbH 51368 Leverkusen, Germany 
9 Atropinsulfat Braun 0,5mg. B.Braun Melsungen AG ,34209 Melsungen, Germany 
 17
with the help of an animal laryngoscope10 using an endotracheal guide11 and ventilated by means 
of a ventilator12. Ventilator settings were adjusted to obtain normocapnia. 
Catheterisation of the internal jugular vein was performed in order to have an access for the 
intravenous administration of narcotics, analgesics, muscle relaxants and electrolytes. 
Anaesthesia was maintained by continuous intravenous injection of 0,08 mg/kg/h Fentanyl13 and 
9, 6 mg/kg/h of Midazolam14. The internal carotid artery was also catheterised and the catheter 
connected to a computer15 by means of a signal transducer16, controlling heart rate and systolic as 
well as diastolic pressure. The limbs of the animal were carefully shaved and disinfected with an 
external antiseptic17. The animals were then fixed in supine position on a special vacuum pouch.  
The surgical procedure consisted of isolating the main arterial and venous vessels of both arms 
and legs so that we could perfuse each of them apart from the main body circulation. This 
operation was performed first in the right inferior extremity and then in the left one. A 
longitudinal incision in the inguinal flexure along the sartorious muscle after trespassing the 
muscle fascia was performed, allowing us to dissect the adjacent tissues to the common femoral 
artery before the division of the lateral femoral artery. Catheterisation of both arterial and venous 
vessels with plastic catheters as well as flushing of the limb with  Ringer’s Lactate of a 
temperature of 4°C were performed, draining the monkey’s blood out of the limb and inducing 
cold ischemia. 
To reach the arm vessels we started with a transversal incision in the axilar region, following the 
opposite order as in the lower extremities (first left arm, then right arm). Once located, the 
brachial artery was fixed with two threads and the axillary vein was isolated. After having 
                                                 
10 Intubationssysteme Draeger, Germany 
11 Safety-Flex© Mallinckrodt Medical; Athione, Ireland. 
12 100-IVB Infant Ventilator; Sechrist Industries.Inc, Anaheim, USA 
13 Fentanyl© Janssen GmbH, Neuss, Germany 
14 Dormicum© H. La Roche AG, Grenzach Whylen, Germany  
15 AMD 486. Digital GmbH, Germany 
16 Plugsys©, HugoSachs Elektronik. March-Hugstetten, 79232 Germany 
17 Kodan©, Shülke&Mair GmbH, Norderstedt, Germany 
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dissected both vessels we ligated them and catheterised them with plastic catheters of 0,9 mm to 
1,1 mm diameter. The arm was then flushed with Ringer’s Lactate18 of 4°C temperature via the 
artery. Our purpose was not only to drain the monkey arm’s blood but also to minimise the 
reperfusion injury by means of reducing the time of warm ischemia and to study the effect of 
different ischemia times in the tissues . 
A plastic string19 placed close to the hip respectively shoulder joint was used for compression in 
order to prevent reflux of the perfusing human blood into the systemic circulation. Blood gases 
as well as cell counts were evaluated in arterial blood samples from the animal during the 
surgical preparation. 
 
2.5. Preparation of human blood 
The haematocrit of the blood used to perfuse the monkey limbs was adjusted to a value of 30% 
(+ 2%) by adding Krebs-Henseleit-buffer20 (144). This facilitates the perfusion by decreasing the 
viscosity of the blood without jeopardising tissue oxygenation (194). For intravital microscopy 
(IVM), plasma was stained with sodium fluoresceine21 and the leucocytes with Rhodamine 6-G 
(0,096 mg/ml)22 (97), added to the blood prior to the reperfusion. 
The three different ATGs23 were added to the human blood 30 minutes before the perfusion with 
a standard dosage of 1ml/kg. The human blood was perfused at a constant temperature of 37 C° 
into the animal limbs through the arterial vessel with the help of a perfusion system that will be 
explained in further chapters.  
 
                                                 
18 Ringer’s-Lactat-Infusionslösung; B.Braun Melsungen AG, 34209 Melsungen, Germany 
19 ISR LMU. München, Germany 
20 ISR-LMU; München, Germany 
21 Fluoresceinisothiocyanate Isomer I, Sigma Chemical Co., St. Louis, USA 
22 Rhodamin© Merck, Darmstadt, Germany 
23 ATG-Biotest, Biotest GmbH, Dreieich, Germany 
    ATG-Fresenius, Fresenius kabi GmbH, Bad Homburg, Germany 
    ATG-Merieux, Imtix Sangstat, California, USA 
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2.6. Perfusion system 
The perfusion system (Fig. 1) (194) consisted of a custom made steel blood reservoir24 with a 
volume of 500 ml. The blood was pumped from the reservoir into a custom-made aluminium 
oxygenator25 by means of a roller pump26. Both reservoir and oxygenator were equipped with a 
heating system27, allowing maintenance of a constant blood temperature of 37 °C (194). A 
computer28 was linked to the system via either a pressure transducer29 or a flow probe30, allowing 
to adjust both parameters. The human blood flowed through a hemo-filter (pore size: 60µm.)31 
and a bubble trap 32 and was finally directed to the isolated arterial vessel of the limb. After 
circulation through the limb, the blood was drained from the vein and re-directed to the reservoir.  
 
2.7. Intravital Microscopy 
Intravital microscopy (IVM) was performed to investigate the microcirculatory parameters and 
endothelial-leukocyte interaction. For this purpose we stained the plasma with sodium 
fluoresceine and the leukocytes with Rhodamine 6-G before placing the human blood into the 
system. Heparin served as anticoagulant. 
A capillary window was opened in the surface of the elbow for the upper limbs and below the 
knee for the lower. During perfusion, microcirculation of these capillary windows was directly 
investigated using a fluorescence intravital microscope33 with epi-illumination and different filter 
blocks34. The IVM investigation is the main subject of the doctoral thesis of D. Chappell. The 
                                                 
24 ISR-LMU, München, Germany 
25 ISR-LMU, München, Germany 
26 IPS,Ismatec SA, Zürich, Switzerland 
27 ISR-LMU, München, Germany 
28 AMD-486DX,Digital GmbH, München, Germany 
29 COMP DT-Xx, Ohmeda, Murray-Hill, NJ, USA. 
30 Transonic Flow Probe, Transonic Systems Inc. Ithaca, NY, USA 
31 Swinnex 25,Milipore,Eschborn, Germany 
32 Becton Dickinson, Heidelberg, Germany 
33 Orthoplan©; Leitz GmbH; Wetzlar, Germany 
34 Fa. Leitz, München, Germany 
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microscopic pictures were transferred via a CCD-camera35 to a video monitor36 and recorded 
with a SVHS video recording unit37. The system settings are illustrated in figure number 1. 
 
 
 
 
 
 
 
Figure 1: Perfusion system (with permission, Xenotransplantation 2001 8:95) 
 
2.8. Blood samples. Blood parameters 
2.8.1. Monitoring of the animal 
Blood samples were collected during the two different phases of our experiments. During the 
surgical procedure, 2 ml blood samples were taken with the help of a 2 ml syringe38 from the 
carotid artery at the time points 0, 15, 30, 45, 60, 90, 120 minutes. These samples were 
transported in Eppendorf cups39 and analysed with a Cell Counter40 to measure the following 
blood parameters during the surgical procedure: leukocytes, erythrocytes, platelets, haematocrit 
and haemoglobin. The same blood samples were used at the time points 0, 30 and 60 minutes to 
measure the PO2, PCO2, pH and HCO3 levels with the help of a gas analyser. Additional samples 
were collected in order to measure gas levels when needed to control the state of the animal. 
                                                 
35 C2400-08,Fa.Hamamatsu Photonics,Herrsching, Germany 
36Wv-5470, Panasonic, München, Germany 
37 AG-7350, Panasonic, München, Germany 
38 Braun Injekt 2ml B.Braun Melsungen AG, 34209 Melsungen, Germany 
39 Sarstedt, 51588 Nümbrecht, Germany 
40 Coulter© Counter Ac T8, Coulter Electronics. Ltd , Luton, UK 
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Blood samples were collected from the donated blood before and after the blood was diluted to a 
haematocrit of 30% and the parameters mentioned above were also measured. These blood 
samples were named –1 for the donor blood and 0 for the diluted blood.  
 
2.8.2. Blood samples during the perfusion 
During the perfusion of the limbs, blood samples were collected from the perfusion system. 2 ml 
arterial blood samples were taken at the time points 1, 5, 10, 15, 30, 45 and 60 minutes after 
onset of reperfusion to measure blood parameters of the perfusate, storing these 14 ml ( 2 ml x 7 
time points) of  blood to perform cytological and immunocytochemical studies. At the time 
points 1, 15, 30, 45 and 60 minutes 2 ml of blood were collected to measure the oxygenation 
level of the perfusate.  
Blood parameters studied in our experiments were: 
• Erythrocytes (RBC) : Expressed in x106/µL 
• Leukocytes (WBC) : Expressed in x10³/µL 
• Platelets (Plat) : Expressed in x10³/µL 
• Haematocrit (Hct) : Expressed in % 
• Haemoglobin (Hb) : Expressed in mg/dl 
2.9. Smears 
Blood smears were performed to evaluate and quantify the presence and morphology of myeloid 
and erythroid cells in whole blood. Blood was anticoagulated with heparin. One drop of well 
mixed blood was spread over a glass slide41, dried and stained by hand or automatically with: 
- May-Grünwald solution42 for    3-4 minutes 
- Aqua dest. rinsing43                   2 minutes 
                                                 
41 Menzel-Glaser GmbH, München, Germany 
42 ISR-LMU, München, Germany 
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- Giemsa solution44 (1/20)   for    15-20 minutes 
- Aqua dest. rinsing                      2 minutes 
 
The dyes were prepared freshly and filtered daily. After drying, the slides were covered with a 
plastic slide45. A general view for rough information was performed using a x100 magnification, 
while x400-x600 magnifications were used to evaluate preparations with a light microscope46.  
 
2.10. Cyto-immunological Monitoring (CIM) 
CIM is a non invasive and non traumatic method for diagnosing inflammatory events in the 
postoperative phase of transplantation. CIM is based on the observation that lymphocytes as well 
as their activated forms disseminate from the rejecting graft modulating the recipient’s lymphoid 
organs (64). 
CIM consists of two tests. The first of them is a fast cytological differentiation of white blood 
cells separated from the peripheral blood that inform roughly about inflammatory events. This 
test should be used when there is no clinical sign of rejection or inflammation. The second test is 
called extended test and consists of the differentiation of mononuclear cell subpopulations by 
immunological methods and should be applied immediately in case of clinical signs of acute 
rejection or infection. We performed CIM as a reliable method to establish the diminution and 
activation of these cell populations. 
After the smear was prepared, the rest of the blood was separated over a Ficoll-Hypaque gradient 
of a density of d=1,077 according to the method of Böyum (64). 0,5 ml of blood mixed with the 
                                                                                                                                                             
43 B.Braun Melsungen AG 34209 Melsungen, Germany 
44 ISR-LMU, München, Germany 
45 Dako GmbH, Hamburg, Germany 
46 Carl Zeiss,37030 Göttingen, Germany 
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same amount of PBS47 were carefully layered over 0,5 ml of Ficoll. Every micro tube48 (1,5 ml) 
was spun at 3200 rpm for 2 minutes in a centrifuge49 and the interphase ring consisting of 
mononuclear cells was transferred to a new microtube and washed two times with PBS. The 
mononuclear concentrate was divided into the machine cuvettes50 and centrifuged for 5 minutes 
at 500 rpm. After this procedure the cytopreps were dried and stained following the May-
Grünwald-Giemsa technique or frozen for immunoperoxidase staining and further 
immunohistochemical studies. 
Cytological slides of the mononuclear concentrate were studied according to a fixed schedule of 
microscope magnification. A general view for rough information was performed using x100 
magnification, while x400-x600 were used to evaluate preparations with no signs of activation. 
In case of cell activation x1000 magnification was employed. Evaluation was performed with the 
help of a light microscope. All immature and polymorphonuclear cells were taken into 
consideration. 
 
2.11. Biopsies 
Biopsy material was obtained from muscle and connective tissue from the limbs of the monkeys 
at the end of the experiment. The biopsies were snap-frozen in liquid nitrogen51 at a temperature 
of –192 C° and stored at –80 C° in an industrial fridge52 for later immunohistological 
investigation. Other specimens were stored in 8% formaline53  for 48 to 72 hours and fixed in 
                                                 
47 Biochrom KG, D-1000 Berlin, Germany 
48 Nunc Cryo Tube© vials, Nalge nunc International, Denmark 
49 Centrifuge 5415 C©, Eppendorf GmbH, 23331 Hamburg, Germany 
50 Eppendorf GmbH, 23331 Hamburg, Germany 
51 Messer Griesheim, 57555 Euteneuen, Germany 
52 Colora UF85-4605©, Colora MessTechnik, Germany 
53 Apotheke Klinikum Großhadern-LMU, München, Germany 
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paraffin54 for later immunohistochemical and histological studies. The biopsies were assigned to 
eight groups according to the ATG employed and the ischemia duration. 
Histological sections of 6 µm were cut from the paraffin-embedded tissue, dehydrated and fixed 
in xylol55 for later immunohistochemical studies. 
The frozen biopsies were cut in 4-µm to 7-µm cryostat56 sections at a temperature of –15 C°, air-
dried and fixed in acetone57 for 10 minutes. H/E was performed in one of every ten slices to 
check the adequate orientation of the preparation. 
 
Group Frozen Biopsies Paraffin blocks 
BSI 20 20 
FSI 14 14 
MSI 12 12 
CSI 10 10 
BLI 16 16 
FLI 10 10 
MLI 8 8 
CLI 8 8 
 
Table 4: Distribution of the biopsies within study groups according to the technique employed. 
 
2.12. Histological and immunohistochemical techniques 
Histological and immunohistochemical techniques were performed to evaluate the state of the 
WBC subpopulations, the infiltrate associated to IRI and the cytotoxic effect of the drugs 
employed. Several techniques were used in order to localise the different types of cells, vessels 
                                                 
54 Dako GmbH,Hamburg, Deutschland 
55 Apotheke Klinikum Großhadern-LMU, München, Germany 
56 Microm HM 560, Microm GmbH, 69190 Waldorf, Germany 
57 Apotheke Klinikum Großhadern-LMU, München, Germany 
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and muscle fibres. It was also important to determine the localisation of the cell subsets related to 
the duration of ischemia. These different histological techniques are described as follows:  
 
• Haematoxylin / Eosin (H/E):  
The H/E staining is one of the most often performed histological techniques due to the great 
cellular details obtained by means of a simple procedure. Haematoxylin stains the nuclei of the 
cells with a dark blue colour. Eosin stains the muscle fibres and fibrin with red and the cytoplasm 
of cells with a pale pink colour. Haematoxylin is a cationic colorant while Eosin is an anionic 
colorant belonging to the xanthenes family. 
The preparations were introduced for four minutes in Haematoxylin58, washed with PBS and 
introduced in Eosin59 (solution 1%) during 1-2 minutes. After washing with ethanol60 70% to 
eliminate the rests of Eosin, the slices were covered with a plastic or glass slide, fixed with 
balsam or synthetic glue61. 
 
• Masson’s Thrichrome: 
This technique allows us to differentiate muscle fibres, cell nuclei, fibrin and collagen. Nuclei, 
centrosomes and secreting granules are dyed black, muscle fibres red and collagen blue. The 
preparations are immersed in Eosin solution 30 minutes after deparaffination, washed with aqua 
dest.62, immersed for 30 minutes in a Haematoxylin solution and again washed with aqua dest. 
After that, differentiation in alcohol is performed during 10-30 minutes and the preparations are 
                                                 
58 Apotheke Klinikum Großhadern-LMU, München, Germany 
59 Apotheke Klinikum Großhadern-LMU, München, Germany 
60 Apotheke Klinikum Großhadern-LMU, München, Germany 
61 Dako Diagnostika GmbH,22047 Hamburg, Germany 
62 Apotheke Klinikum Großhadern-LMU, München, Germany 
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stained with fuchsine63 for 5 minutes, washed with aqua dest. and covered with a plastic or glass 
slide. The histological slides are then mounted and fixed with balsam or synthetic glue. 
 
• Granulocyte Esterase (GE): 
This technique allows differentiation of granulocytes from other WBC. Granulocytes are stained 
in a dark violet colour with black nuclei in contrast to no positive staining of lymphocytes and 
monocytes.  
The preparations are immersed for 30 seconds in formaldehyde solution64, afterwards washed 
with aqua dest., then immersed shielded from light during 30 minutes in ASDCL solution65 
(Fast-Red violet66 + Sodium Nitrite + Buffer + Chloroacetate) , washed with aqua dest., stained 
for two minutes with simple Mayer´s Haematoxylin solution, washed with normal water, then 
washed with aqua dest. and finally air dried and covered with a plastic slide. 
 
• CD45 (LCA) : 
The primary antibody anti-CD45 is also called Leukocyte Common Antigen (LCA) due to its 
capacity to stain all cell subsets of WBC by staining the tyrosin-phosphatase present in signal 
transduction of these cells. We were interested in demonstrating the presence or absence of WBC 
after the perfusion with or without ATG. We performed this immunohistochemical staining 
according to standard rules, described in continuation, using an anti-human monoclonal antibody 
from mouse67 . 
                                                 
63 Apotheke Klinikum Großhadern-LMU, München, Germany 
64 Apotheke Klinikum Großhadern-LMU, München, Germany 
65 Apotheke Klinikum Großhadern-LMU, München, Germany 
66 Dako Diagnostika GmbH,22047 Hamburg, Germany 
67 Dako Diagnostika GmbH,22047 Hamburg, Germany 
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The immunohistochemical procedure was performed in 4 nm cryostat sections, air dried and 
fixed in acetone68 for 10 minutes. After incubation with human serum in phosphate-buffered 
saline (PBS)69 for 10 minutes, the sections were incubated with 100 ml of 1:100 and 1:250 
dilutions, in PBS, of the primary antibody overnight at 4 C°. The secondary reaction was 
performed according to Hsu et al.(77) with an ABC complex70 for indirect immunostaining. The 
immunoreaction was developed with 3; 3´-diaminobenzidine tetrachloride71 (DAB) and H2O272 
to prevent cross reactions with endogenous peroxidase, dehydrated and mounted in a glass 
mountant73. 
• Interleukin 4 (IL-4) 
Interleukin 4 (IL-4, B-cell growth factor-1, BSF-1) is a T-cell derived cytokine that plays an 
important role in the activation of resting B-cells, being irreplaceable in the process of activation 
of Th2 lymphocytes.The same procedure as explained for CD45 was applied in this case, using 
an anti-human monoclonal antibody74 against interleukin 4. Immunostaining of IL-4 was 
performed to determine whether ATG had an influence on the cellular expression and release of 
this cytokine and subsequently on the activation of helper lymphocytes. 
• Thrombocytes and Endothelial Cells (CD31) : 
Thrombocytes were stained with indirect immunoperoxidase to localise their presence, 
aggregation and participation in thrombus formation. Immunostaining was done with an anti-
human monoclonal antibody for CD3175. 
                                                 
68 Apotheke Klinikum Großhadern-LMU, München, Germany 
69 Apotheke Klinikum Großhadern-LMU, München, Germany 
70 Sigma GmbH, Hamburg, Germany  
71 Dako Diagnostika GmbH,22047 Hamburg, Germany 
72 Apotheke Klinikum Großhadern-LMU, München, Germany 
73 Dako Diagnostika GmbH,22047 Hamburg, Germany 
74 R&D Systems, Waldorf, Germany 
75 Dako Diagnostika GmbH,22047 Hamburg, Germany 
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The immunohistochemical procedure was performed in 4-7 µm paraffin sections, air dried, and 
fixed in acetone for 10 minutes. After incubation with human serum in phosphate-buffered saline 
(PBS) for 10 minutes, the sections were incubated with 100 ml of a 1:10 dilution, in PBS, of the 
primary antibody at 4°C overnight. The secondary reaction was performed with the streptavidin-
biotin LSAB©76 complex for indirect immunostaining. The immunoreaction was developed with 
3; 3´-diaminobenzidine tetrachloride and H2O2 to prevent cross reactions with endogenous 
peroxidase, dehydrated and mounted in a glass mountant. 
 
• Fibrin:  
Fibrin was stained according to Weiger’s technique. This method allows to differentiate fibrin 
(homogeneous, brilliant pink) from muscle fibres (red). After deparaffination the slices were 
fixed in Chrome77 and treated with permanganate78 . The nuclei were stained with Lithium 
Carmine79, washed in aqua dest., drained in filter paper80, stained with Gentian violet81 for 15-20 
seconds, drained in filter paper, stained with Lugol solution82 for 15-20 seconds, drained in filter 
paper, differentiated with Aniline Oil83 and covered with a plastic or glass slide. 
 
 
2.13. Histological evaluation 
Semiquantitative evaluation of the histological section was done in seven tissue fields per biopsy, 
chosen by coincidence. Different criteria of evaluation were considered according to the staining 
performed. This method is extensively described in the literature (17, 38, 74, 149). We have 
                                                 
76 Dako Diagnostika GmbH,22047 Hamburg, Germany 
77 Apotheke Klinikum Großhadern-LMU, München, Germany 
78 Apotheke Klinikum Großhadern-LMU, München, Germany 
79 Apotheke Klinikum Großhadern-LMU, München, Germany 
80 Dako Diagnostika GmbH,22047 Hamburg, Germany 
81 Apotheke Klinikum Großhadern-LMU, München, Germany 
82 Apotheke Klinikum Großhadern-LMU, München, Germany 
83 Apotheke Klinikum Großhadern-LMU, München, Germany 
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modified the one described by Koo et a. (95). The following criteria were established for the 
histological evaluation: 
 
• Muscle damage: loss of architecture, necrosis or signs of ischemia were considered: 
- normal architecture: 0 
- light damage: 1 
- moderate damage: 2 
- severe damage: 3 
• Soft tissue infiltration: Connective tissues present in the biopsy as well as connective 
perimisial structures were considered. 
- any WBC in these structures: 1 
- more than 10 cells per field: 2 
- more than 25 cells per field: 3 
• Vascular infiltration: Cells present in the vascular spaces were considered, free or attached to 
the endothelial walls. 
- free cells in the vessels: 1 
- free and attached to the endothelial cells: 2 
- free cells, attached cells, granulocytes, occluding or almost occluding 
the vessel lumen: 3 
• Perivascular infiltration: Presence of WBC in any tissue adjacent to the vessels: 
- presence of cells attached to endothelial walls: 1 
- presence of cells in perivascular connective tissue: 2 
- presence of cells in perivascular connective tissue and muscular 
tissue:3  
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• Muscular infiltration:  
-     no cells in muscle fibres: 0 
- 1-5 cells pro muscular fibre: 1 
- >10 cells pro muscular fibre: 2 
- >25 cells pro muscular fibre: 3  
Results are expressed as the mean values obtained from the different fields studied. The 
preparations were labelled with a code and evaluated blindly. 
 
Fibrin, Masson’s T and CD31 immunostaining were performed to localise fibrin and thrombus 
formation and the criteria were established as follows: 
• Presence of fibrin or thrombocytes in the vascular spaces: 
- presence of fibrin or thrombocytes without occlusion: 1 
- occlusion of the vessel: 2  
- occlusion of the vessel and destruction of the vascular or endothelial 
integrity: 3 
A fixed number of vessels, n=7, were studied blindly per section. The results are expressed as the 
mean of the sections studied. 
The immunoreaction with IL4 was classified as positive or negative depending on the presence 
or absence of this molecule in the sections studied. 
 
2.13. Statistical analysis 
Statistical descriptive analysis of the results was performed with Excel84. Data are presented as 
median + standard deviation. The analytical studies were performed with Excel and S-plus 
                                                 
84 Office XP, Microsoft©, NJ, USA 
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statistical programmes85. The method employed was Analysis of Variance (ANOVA) for 
different variables. The variable “time of perfusion“ was studied with Excel. After ANOVA, 
Tukey’s test for normally distributed values and Dunnet’s or Dunn’s tests for non normally 
distributed values were used for posterior multiple comparisons. The variables studied with S-
plus were “drug” and “time of ischemia”. Scheffe´s test was employed “a posteriori” when 
statistical significances were detected between the groups for the variables “time of ischemia” 
and “drug”. We used Scheffe´s test as we needed tests appropriate for multiple comparisons. 
Multiple comparison tests are characterised by considering the number of tests that could be 
made. Scheffe´s test is a valid, fairly conservative test, sufficiently generalised to be applicable 
to unequal designs. Applying this test, all possible contrasts can be tested for significance, or 
confidence intervals constructed for corresponding linear functions of parameters (184).  
The analytical graphics were designed applying the smooth/splining technique to the previously 
mentioned statistical tests. Nonparametric function estimation with stochastic data, otherwise 
known as smoothing, has been largely studied (32). Smoothing spline ANOVA models are a 
versatile family of smoothing methods that are suitable for both univariate and multivariate 
problems. This method allows constructing multivariate models with ANOVA. Statistical 
significance was accepted when p<0, 05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
85 S-plus ©, Microsoft©, NJ, USA 
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3. RESULTS 
3.1 Blood Parameters 
Median and standard deviation values of the following parameters: WBC, RBC, platelets, 
haematocrit and haemoglobin for every time point are presented in the following pages. 
Statistical analysis to investigate the differences between groups was performed. Time point 0 
(blood diluted to a haematocrit of 30%) was taken as control for the study of “time of perfusion” 
as variable. 
3.1.1. WBC 
• Short Ischemia: BSI-FSI-MSI-CSI 
The number of circulating WBC in PB of the CSI showed no decrease. In contrast to this, the 
number of WBC was significantly decreased during reperfusion in the FSI group (p<0.05; Tukey 
test). Decreases of the number of WBC of BSI and MSI showed no statistical significance.  
Fig. 2: WBC-Short Ischemia: Number of WBC in peripheral blood during the reperfusion in SI time. Values are 
given as median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05)  
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• Long Ischemia: CLI, FLI, BLI, MLI 
The number of circulating WBC in PB of the CLI showed no significant decrease. In contrast to 
this, the number of WBC was significantly decreased during reperfusion in the FLI group 
(p<0,05; Tukey test). Decreases of the number of WBC of MLI showed no statistical 
significance (figure 3). However, reperfusion in the BLI group showed a significant decrease in 
the number of WBC after the 15 minute (p<0,05, Tukey test).  
 
Fig. 3: WBC-Long Ischemia: Number of WBC in peripheral blood during the reperfusion in LI time. Values are given 
as median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
 
Further statistical tests with ANOVA were performed between groups according to the length of 
the ischemia time and the drug employed. Differences between the groups were studied. 
Statistically significant differences were found: 
• Drug: p < 0.001 
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• Ischemia Time: p = 0.056 
Scheffe´s test (p < 0.05) was applied “a posteriori” to the drug and the ischemia time variables to 
determine which groups presented differences between them according to the following factors: 
• The number of circulating WBC in the three ATG groups was statistically lower than   
the number of WBC in the control group both for SI and LI times (p<0,05).  
• Applying the test to the ischemia time, only the group Merieux presented significant 
differences between short time and long time of ischemia, showing a higher number of 
WBC in MLI than in MSI (p<0,05).  
These significances can be expressed graphically through smoothing-spline of ANOVA and 
Scheffe´s test, allowing one to create a theoretical model of the variable in relation to the groups 
studied. 
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Fig. 4: Smoothing-Spline of WBC: The number of circulating WBC in the three ATG groups was statistically lower 
than the number of WBC in the control group both in SI and LI times (*Control vs. Biotest-ATG; § Control vs. 
Fresenius-ATG; # Control vs. Merieux-ATG: p<0,05). 
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Fig. 5: Smoothing-Spline of WBC: Only Merieux-ATG groups experienced statistically significant differences 
between long and short ischemia in the number of WBC, these being significantly higher in LI times (# Merieux LI 
vs. Merieux SI: p< 0,05). The other groups, including control, showed no statistical significance. 
 
3.1.2 RBC  
 
• Short Ischemia: BSI-FSI-MSI-CSI 
Analysis of the circulating number of RBC during perfusion with human blood treated with a 
standard dosage of ATG (1mg/kg) after a short ischemia period showed the following results. 
CSI, MSI and FSI groups presented no significant variation of the number of RBC during the 
reperfusion. BSI group, however, showed a significant increase of the number of circulating 
RBC at the end of the reperfusion (p< 0,05, Dunn’s test). 
 
 
 
# 
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Fig. 6: RBC-Short Ischemia: Number of RBC in peripheral blood during the reperfusion in SI time. Values are given 
as median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
 
 
• Long Ischemia: CLI, FLI, BLI, MLI 
The number of RBC after long ischemia showed the following results. BLI and FLI groups show 
an increasing tendency (p< 0,05, Tukey’s test) while the values of erythrocytes in the control and 
MLI group present no statistically significant difference between the time points of the 
reperfusion.  
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Fig. 7: RBC Long Ischemia: Number of RBC in peripheral blood during the reperfusion in LI time. Values are given 
as median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05)                                                                           
 
Comparisons between ATG groups and controls were performed as well as comparison between 
each ATG group. The circulating number of RBC showed statistical differences for the next 
variables: 
• Drug: p < 0.001 
• Ischemia Time: No significance was demonstrated 
We applied the Scheffe´s test to the drug variable to determine differences between ATG groups 
and control in relation to RBC. All three ATG groups presented statistically significant higher 
values of RBC during the reperfusion time with a p < 0.05. No further studies were performed 
taking “ischemia time” as variable, because no significant differences were found in the general 
ANOVA test. 
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Fig. 8: Smoothing-Spline of RBC for SI and LI: The number of RBC in the three ATG groups  was significantly 
higher than the number of RBC in the control group both in SI and LI ischemia times (*Control vs. Biotest-ATG; § 
Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: p<0,05). 
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Fig. 9: Smoothing-Spline of RBC for SI and LI: No differences according the ischemia time were found within the 
groups. 
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3.1.3. Platelets 
 
• Short Ischemia: BSI-FSI-MSI-CSI 
Analysis of the number of circulating platelets in peripheral blood throughout reperfusion with 
human blood after short ischemia showed the following results. In the short ischemia groups 
only the BSI group showed a statistically significant decrease of the number of platelets during 
the reperfusion (p< 0,05, Tukey’s test).  
 
Fig. 10: Thrombocytes-Short Ischemia: Absolute numbers of platelets in PB during reperfusion after SI time. 
Observe the decrease of the number of thrombocytes in the Biotest-ATG group (BSI). Values are given as median 
and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
  
• Long Ischemia: CLI, FLI, BLI, MLI 
Analysis of the number of circulating thrombocytes after long ischemia showed the following 
results. BLI and MLI presented a significant decrease of the number of platelets during the 
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reperfusion (p< 0,05, Tukey’s test). In contrast to this, FLI and CLI showed no significant 
differences.  
 
Fig. 11: Thrombocytes-Long Ischemia: Absolute numbers of platelets in PB during the reperfusion after LI time. 
Observe the decrease of the number of thrombocytes in the Biotest-ATG group (BSI). Values are given as median 
and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
 
The number of peripheral thrombocytes showed differences between the ATG groups and 
control as well as differences within the ATG groups. Variable “drug” showed a statistical 
significance of p< 0,001, while “ischemia time” showed no general significance. Scheffe´s test 
was applied to “drug” and “ischemia time” variables to assess further differences within the ATG 
and the control groups. According to the ATG added, the results were as follows: The numbers 
of platelets remained at values between 100 and 250 x 10³/µL for both the control groups and the 
Fresenius groups. The numbers of platelets for the Merieux and the Biotest groups decreased. 
The statistical significance accepted was p< 0, 05. Control showed a statistically significant 
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higher number of platelets when compared with Biotest and Merieux groups for both long and 
short ischemia times. 
Applying the Scheffe´s test to the ischemia time, only the Merieux ATG group showed a 
significant difference on the number of peripheral thrombocytes with different ischemia times. 
The number of thrombocytes was higher in the MLI group. Control and the other two ATG 
groups showed no significant difference. However, the ischemia time as an independent variable 
has an influence when comparing the different drugs in short other long time of ischemia. ATG-
Fresenius presents no statistical difference in number of platelets when compared to the Merieux 
group in LI Time, although this difference exists in the SI time. By means of smoothing-spline a 
multivariate model of the number of platelets under these conditions was designed (Figs. 12, 13). 
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Fig. 12: Smoothing-Spline of Thrombocytes for SI and LI : The number of platelets in the control group was 
significantly higher than the number of platelets in the Biotest-ATG and Merieux-ATG groups  both for short and 
long ischemia times. Number of platelets of the Fresenius-ATG group was significantly higher than the number of 
thrombocytes of the Merieux-ATG group (*Control vs. Biotest-ATG; # Control vs. Merieux-ATG; § Fresenius-ATG 
vs. Merieux-ATG: p<0, 05). 
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Fig. 13: Smoothing-Spline of Thrombocytes for SI and LI : After statistical analysis, only the Merieux ATG group 
showed a significant difference in the  number of  peripheral thrombocytes with different ischemia times, the amount of 
thrombocytes being higher in the LI group. (# Merieux LI vs. Merieux SI: p<0, 05) 
 
3.1.4 Haematocrit  
• Short Ischemia: BSI-FSI-MSI-CSI 
Analysis of the human blood haematocrit during the whole process of reperfusion with human blood 
showed the following results. Analysis of the perfusion time is made after time point 0 (blood 
dilution), which serves as control. BSI group showed a statistically significant increase of Hct 
(p<0,05, Dunn’s test) while FSI, MSI and CSI presented no significant differences. 
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Fig. 14: HCT in %- Short Ischemia: haematocrit in % during the reperfusion after SI time. Values are given as 
median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05)  
 
• Long Ischemia: BLI, FLI, MLI, CLI 
Analysis of the haematocrit during reperfusion with human blood after a LI period expressed the 
following variations. BLI and FLI presented a statistically significant increase of the Hct at the 
end of the reperfusion (p< 0,05, Dunn’s test). In contrast to this, CLI and MLI experienced no 
significant variation. 
Fig. 15: HCT in %- Long Ischemia: haematocrit in % during the reperfusion in LI time. Values are given as 
median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
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As explained in material and methods the blood was diluted with Krebs-Henseleit-Buffer 
solution to a haematocrit of 30%. The variations of this value were studied with statistical 
methods and the results compared within the different groups. Ischemia time as a variable 
showed no statistical signification. However, “drug”, taken as variable, showed statistical 
signification with p<0,001. After applying the Scheffe´s test to the “drug” variable, we 
observed that the decrease of haematocrit of the control groups was statistically significant 
with a p<0.05. This difference exists also when the analysis is performed for both times of 
ischemia. 
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Fig. 16: Smoothing-Spline of haematocrit in %: The Hct in the three ATG groups  was significantly higher than in 
the control group both in short and long ischemia times (*Control vs. Biotest-ATG; § Control vs. Fresenius-ATG; # 
Control vs. Merieux-ATG: p<0,05). 
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Fig. 17: Smoothing-Spline of haematocrit in %: No statistically significant differences were found according to the 
length of the ischemia times within the study groups. 
 
3.1.5 Haemoglobin (Hb)  
• Short Ischemia: BSI-FSI-MSI-CSI 
Amount of haemoglobin in the different groups during the whole reperfusion was investigated. 
BSI group showed a statistically significant increase of Hb (p< 0,05, Tukey’s test) while FSI, 
MSI and CSI presented no significant differences. 
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Fig. 18: Hb (g/dl)-Short Ischemia: Amount of Hb of the study groups after a SI period. Values are given as 
median and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05)  
• Long Ischemia: 
Haemoglobin values in the different study groups after a LI period showed the following results. 
BLI and FLI presented a statistically significant increase of the Hct at the end of the reperfusion 
(p< 0,05, BLI: Dunn’s test; FLI: Dunnet’s test). In contrast to this, CLI and MLI experienced no 
significant variation. 
Fig. 19:Hb (g/dl)-Long Ischemia: Amount of hb of the study groups after a LI period. Values are given as median 
and standard deviation. *Time point vs. Control [Time point 0] (p<0, 05) 
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The haemoglobin values are substantially related to the values of erythrocytes and haematocrit. 
Therefore they present a similar behaviour after ATG treatment. The “ischemia time”, taken as 
variable alone, showed no significant differences between the ATG groups and the control 
groups. “Perfusion time” and “drug” presented statistically significant differences for p< 0,001. 
When we consider the variable “drug” , the values of haemoglobin in the ATG groups are higher 
than in the control groups, the same as happened before with erythrocytes and haematocrit. The 
differences between them after applying the Scheffe´s test are statistically significant (p<0, 05). 
There are no variations when we study the drug group dependent on the ischemia time. A 
multivariate model for haemoglobin values with smoothing is shown in the next figures (Figs. 
20, 21). 
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Fig. 20: The haemoglobin amount (g/dl) in the three ATG groups was significantly higher than in the control group 
both in short and long ischemia times (*Control vs. Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. 
Merieux-ATG: p<0,05). 
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Fig. 21: Smoothing-Spline of haemoglobin amount: No statistically significant differences were found according to 
the length of the ischemia times within the study groups. 
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3.2 Smears 
The percentages of lymphocytes, neutrophils and monocytes were measured as described in 
Material and Methods. Eosinophil and LGL percentages are not shown as their values are not 
significant for the study. Results for the different ATGs are assigned according to the time of 
ischemia. Short ischemia (SI) time was 60 + 10 minutes and long ischemia (LI) 120 + 10 
minutes. Descriptive and comparative results for each group are expressed as median + standard 
deviation in the graphics. The results are presented according to the following order: first the 
results of SI groups, then of the LI groups. Comparisons between groups and between different 
times of ischemia are shown at the end of each parameter. 
 
3.2.1 Lymphocytes 
 
• Short Ischemia: BSI, FSI, MSI, CSI 
Blood smears were performed with samples obtained from everyone of the four groups studied to 
evaluate the percentage of lymphocytes in PB and to compare it between the different ATG 
groups and control groups. In SI groups the samples were taken from the system after a period of 
short ischemia (60 + 10 minutes). No significant differences in the percentage of lymphocytes 
during the reperfusion were found within the groups. 
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Fig. 22: Lymphocytes-Short Ischemia: Percentage of lymphocytes in PB smears during the reperfusion after a 
SI period ( median and standard deviation are expressed in %). 
 
• Long Ischemia: BLI, FLI, MLI, CLI 
The percentage of lymphocytes in the LI groups is expressed in the following tables and figures. 
No significant differences in the percentage of lymphocytes during the reperfusion were found 
within the groups. 
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Fig. 23: Lymphocytes -Long Ischemia: Percentage of lymphocytes in PB smears during the reperfusion after a 
LI period (median and standard deviation are expressed in %). 
 51
The number of lymphocytes differentiated by means of cytology blood smears was substantially 
diminished in the ATG groups as compared to the control groups. Statistical tests with ANOVA 
were performed between groups according to the time of perfusion, the time of ischemia and the 
drug employed. After analysis, only the variable “drug” presented statistical significance, with a 
p < 0.001. Scheffe´s test was applied to further investigate this significant difference between 
groups. There is a statistically significant decrease in the number of lymphocytes in all the ATG 
groups when compared to the control group (p<0,05). “Ischemia Time” as variable did not show 
significant differences except for the Merieux group, presenting lower values of lymphocytes in 
the LI group (p<0.05). These results are expressed as a multivariate model of smoothing for 
ANOVA in the next figure. 
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Fig. 24: Smoothing-Spline of lymphocytes according to the drug and ischemia time: The percentage of lymphocytes 
in the three ATG groups was statistically lower than in the control group, both after SI and LI times (*Control vs. 
Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: p<0,05). 
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Fig. 25: Smoothing-Spline of lymphocytes according to the drug or ischemia time: Only Merieux-ATG groups 
experienced statistically significant differences between long and short ischemia percentage of lymphocytes, being 
significantly higher in SI time (# Merieux SI vs. Merieux LI p< 0.05). The other groups, including control, showed 
no statistical significance. 
 
3.2.2 Neutrophils 
• Short Ischemia: BSI, FSI, MSI, CSI 
The percentage of neutrophils in PB was evaluated in SI groups throughout reperfusion with 
human blood. No significant differences were found within the study groups according to the 
time of perfusion. 
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Fig. 26: Neutrophils-Short Ischemia: Percentage of neutrophils of the different study groups during the reperfusion 
(median and standard deviation are expressed in %). Note: the decrease of the % of neutrophils in the control group 
in comparison to the three ATG groups. 
• Long Ischemia: BLI, FLI, MLI, CLI 
The percentage of neutrophils in blood smears was also investigated in LI groups. No significant 
differences were found within the study groups according to the time of perfusion. 
Fig. 27: Neutrophils-Long Ischemia: Descriptive graphics of the percentage of neutrophils of the different study 
groups during the reperfusion (median and standard deviation are expressed in %). 
The percentage of neutrophil granulocytes in the different ATG and control groups was 
investigated. Higher percentages of neutrophils in the ATG groups in comparison to the control 
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groups were observed with the help of descriptive statistics. Further analysis was performed with 
ANOVA. Time of ischemia, drug and time of perfusion were selected as dependent variables. 
Time of perfusion and time of ischemia did not show any significant difference in the percentage 
of neutrophils in the general statistical study, while “drug” as a variable presented statistically 
significant differences of the % of neutrophils within the different groups with a p<0,001. 
Scheffe´s test to study the intragroup differences for a statistical significance was performed “a 
posteriori” taking “drug” as independent variable. Control groups presented significantly less 
neutrophils when compared to the ATG groups (p<0.05). However, considering ischemia time as 
an independent variable, there is no significance between control and the ATG-Fresenius group 
in the LI time, while the other groups results remain unaltered. 
                                           Smears: Neutrophils 
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Fig. 28: Smoothing-Spline of neutrophils according to the drug or ischemia time: The % of neutrophils in the three 
ATG groups was significantly higher than in the control group for SI time. Percentage of neutrophils in the Biotest-
ATG and the Merieux ATG groups was significantly higher than in the control group after LI time (*Control vs. 
Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: p<0, 05). 
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Fig. 29: Smoothing-Spline of neutrophils: No statistically significant differences were found according to the length 
of the ischemia times within the study groups. 
 
3.2.3 Monocytes 
• Short Ischemia: BSI, FSI, MSI, CSI 
Blood smears were performed to evaluate the percentage of monocytes in PB and compare the 
values of the different ATG and the control groups. The percentage of monocytes is much lower 
than those of lymphocytes and neutrophils. That is the reason why a different scale is used for 
the graphics. No significant differences were found within the study groups according to the time 
of perfusion.  
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Fig 30: Monocytes-Short Ischemia: Percentage of monocytes during the reperfusion after a SI period (median and 
standard deviation are expressed in %). 
 
• Long Ischemia: BLI, FLI, MLI, CLI 
The percentage of monocytes in the different groups was assessed. A different scale has been 
employed also in the long ischemia groups. No significant differences were found within the 
study groups according to the time of perfusion. 
Fig. 31: Monocytes-Long Ischemia: Percentage of monocytes during the reperfusion after LI time (median and 
standard deviation are expressed in %).  
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The percentage of monocytes did not present much variation between groups in the 
cytological studies. ATG-Merieux group presented a significant increase of monocytes in LI, 
considering Ischemia as independent variable.  
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Fig. 32: Smoothing-Spline of monocytes: No significant differences were found after statistical analysis. 
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Fig. 33: Smoothing-Spline of monocytes according to ischemia time: Only Merieux-ATG groups experienced 
statistically significant differences between SI and LI percentage of monocytes, being significantly higher in LI 
times (# Merieux SI vs. Merieux LI p< 0.05).  
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3.2.4. Microphotographs 
 
The following figures are microphotographs obtained from the smears performed with every 
blood sample. The high number of smears evaluated does not allow us to present all the images. 
These pictures try to reflect the standard behaviour of both the control and study groups. As a 
general rule, more mononuclear cells in whole blood can be observed in the control groups and 
more polymorphonuclear cells are to be seen in the study groups. All pictures are shown as 
microscope magnifications. 
 
1. Biotest Short Ischemia: BSI 
 
Fig. 34: Higher proportion of polymorphonuclear cells was observed in the ATG groups. However, mononuclear 
cells were also seen (Fig. 34-A x20). Damaged WBC can be observed at a higher magnification after treatment with 
ATG (Fig. 34-B x100) 
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2. Biotest Long Ischemia: BLI 
 
Fig. 35: In the BLI group, a higher percentage of lymphocytes than in other ATG groups was observed at the 
beginning of the reperfusion (Fig. 35-A x20). No significant differences were detected between the ATG groups. 
Segmented granulocytes were seen at a higher magnification (Fig. 35-B x100) 
 
3. Fresenius Short Ischemia: FSI 
 
Fig. 36: In the FSI group, few mononuclear cells were observed both at low and high magnification (Fig. 36-A x20, 
Fig. 36-B x100) 
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4. Fresenius Long Ischemia: FSI 
 
Fig. 37: More cells were seen in the FLI group in comparison to FSI group, although no statistically significant 
difference was observed. Presence of mononuclear cells was low in comparison to polymorphonuclears. (Fig-37-A 
x20, Fig. 37-B x100) 
 
5. Merieux Short Ischemia: MSI 
Fig. 38: A lower amount of cells was seen in the MSI group in comparison to the control groups. There were more 
polymorphonuclear cells (Fig. 38-A x40) although lymphocytes were also observed (Fig. 38-B x100) 
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6. Merieux Long Ischemia: MLI 
 
Fig. 39: MLI group presented fewer lymphocytes than the MSI group, but a higher percentage of monocytes (Fig. 
39-A x40). At a higher magnification, a segmented polymorphonuclear cell is shown (Fig. 39-B x100) 
 
7. Control Short Ischemia: CSI 
 
Fig. 40: CSI group presented a higher number of mononuclear WBC (Fig. 40-A x40, Fig. 40-B x100) 
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8. Control Long Ischemia: CLI 
 
Fig. 41: At the end of the reperfusion, the CLI group presented a high number of cells per smear. The percentage of 
lymphocytes was much higher than other WBC in comparison to the ATG groups. (Fig. 41-A x20, Fig. 41-B x40) 
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3.3. CIM 
Descriptive results for each group are presented as median + standard deviation in the graphics. 
Comparisons between groups are described in the text and shown in the figures. The results are 
expressed according to the following order: first results of the SI groups are shown, then of the 
LI groups. Analysis of the time of perfusion is performed taking 0 as control point (blood diluted 
to 30% Hct). Comparisons between groups and between different times of ischemia are also 
shown. 
 
3.3.1 Lymphocytes 
• Short ischemia: BSI, FSI, MSI, CSI 
 
 
CIM of the four groups studied evaluated the percentage of lymphocytes differentiated in WBC 
subpopulations. The results were compared between the ATG and control groups. In SI groups 
the samples were taken from the system after a period of short ischemia (60 + 10 minutes). CSI 
and MSI showed no significant differences according to time of perfusion. In contrast to this, the 
percentage of lymphocytes decreased in the BSI and FSI ATG groups throughout the 
reperfusion. (p<0,05; BSI: Dunn’s test; FSI: Tukey’s test). 
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Fig. 42: Lymphocytes-Short Ischemia: Percentage of lymphocytes in CIM in the different study groups after a SI 
period (median and standard deviation are given in %). *Time point vs. Control [Time point 0] (p<0, 05).  
 
• Long Ischemia: BLI, FLI, MLI, CLI 
 
CIM was performed in samples obtained from every of the four groups studied to evaluate and 
compare the percentage of lymphocytes. In these groups the samples were taken from the arterial 
branch of the system after a LI period. MLI presented a statistically significant decrease of the 
percentage of lymphocytes throughout the reperfusion (p<0,05; MLI: Tukey’s test). In contrast to 
this, no significant differences were observed in CLI, BLI and FLI groups. 
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Fig. 43: Lymphocytes-Long Ischemia: Percentage of lymphocytes with CIM after a LI period (median and standard 
deviation are given in %). *Time point vs. Control [Time point 0] (p<0, 05). 
 
The percentage of lymphocytes as WBC subpopulation was investigated according to three 
different variables: “time of perfusion”, “drug” and “time of ischemia. Differences between the 
groups were studied showing that both the variables “drug” and “perfusion time” presented 
statistical significance, with a p< 0.001 (as shown in the previous graphics). Factor “ischemia 
time” showed no significance in the general test. Scheffe´s test was applied to further investigate 
this significant difference between groups for the “drug” variable. The percentage of 
lymphocytes of the three ATG groups presented a statistically significant decrease when 
compared to the control group throughout the reperfusion process (p<0, 05). This significance 
remained unaltered when the groups were compared according to the time of ischemia. In the 
particular tests between groups, no significance for “ischemia time” was found. 
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Fig. 44: Smoothing-Spline of lymphocytes (CIM): The percentage of lymphocytes among WBC in the three ATG 
groups  was significantly lower than in the control group both in SI and LI times (*Control vs. Biotest-ATG; § 
Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: p<0,05). 
-20 0 20 40 60
-20 0 20 40 60
TIME
0
20
40
60
80
0
20
40
60
80
Ly
m
ph
. %
CIM: Lymphocytes
CONTROL BIOTEST
FRESENIUS MERIEUX
SI
LI
 
 
Fig. 45: Smoothing-Spline of lymphocytes according to ischemia time: No statistically significant differences were 
found according to the length of the ischemia times within the study groups. 
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3.3.2 Neutrophils 
 
• Short Ischemia: BSI, FSI, MSI, CSI 
 
The percentage of neutrophils in differentiated WBC subpopulation was compared within the 
different ATG groups and the control groups. The samples were taken from the arterial branch of 
the system after a SI period (60 + 10 minutes) and processed as described before. BSI and FSI 
groups experienced a significant increase of the percentage of neutrophils (p<0,05; Tukey’s test). 
MSI and CSI, however, showed no statistically significant differences. 
 
 
 
Fig. 46: Neutrophils-Short Ischemia: Percentage of neutrophils after a SI period (median and standard deviation 
are given in %). *Time point vs. Control [Time point 0] (p<0, 05). 
 
• Long Ischemia: BLI, FLI, MLI, CLI 
CIM was performed in samples obtained from each of the four groups studied to evaluate the 
percentage of neutrophils within the different groups and compare the obtained results. MLI 
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presented a significant intragroup increase of the percentage of neutrophils throughout the 
reperfusion. In contrast to this, BSI, FSI and CSI showed no statistically significant difference. 
 
Fig. 47: Neutrophils-Long Ischemia: Percentage of neutrophils in the different study groups after a LI 
period(median and standard deviation are given in %). *Time point vs. Control [Time point 0] (p<0, 05). 
 
The relative number of neutrophils was investigated in the different experiment groups and the 
results obtained were compared according to three different variables: “time of perfusion”, 
“drug” and “time of ischemia”. Statistical tests with ANOVA were performed showing statistical 
significance for “time of perfusion” and “drug” with a p<0,001. “Time of ischemia” presented a 
significance of p=0,084. Taking “drug” as independent variable, the Scheffe´s test showed that 
there is statistical significance between the percentage of neutrophils in ATG-Fresenius and 
ATG-Biotest groups, this being higher in the ATG-Biotest groups (p<0,05). No drug showed 
statistical differences for the percentage of neutrophils dependent on the length of the ischemia 
Neutr-BLI
0
20
40
60
80
100
-1 0 1 5 10 15 30 45 60
Time
N
eu
tr
 %
Neutr-BLI
Neutr-FLI
0
20
40
60
80
100
-1 0 1 5 10 15 30 45 60
Time 
N
eu
tr
 %
Neutr-FLI
Neutr-MLI
0
20
40
60
80
100
-1 0 1 5 10 15 30 45 60
Time
N
eu
tr
 %
Neutr-MLI
Neutr-CLI
0
20
40
60
80
100
-1 0 1 5 10 15 30 45 60
Time
N
eu
tr
 %
Neutr-CLI
              *   *   *            
 69
time. However, the difference between the ATG-Fresenius and ATG-Biotest groups could only 
be demonstrated for the short ischemia time when we accepted “time of ischemia” as 
independent variable and drug as dependent variable in the Scheffe´s test (p<0,05). No 
significance for this difference was accepted in the LI time between both groups while the 
percentage of neutrophils in the control group was lower than in the three ATG groups in LI 
time.  
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Fig. 48: Smoothing-Spline of neutrophils (CIM): The percentage of neutrophils of the Biotest-ATG group was 
significantly higher than the percentage of neutrophils in the Fresenius-ATG group only in the SI time. The 
percentage of neutrophils in the control group was lower than the three ATG groups in LI time ($ Fresenius-ATG 
group vs. Biotest-ATG group; *Control vs. Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: 
p<0,05). 
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Fig. 49: Smoothing-Spline of neutrophils: Only the control groups showed significant differences between SI and LI 
times, being the percentage of neutrophils higher in the SI time. (* Control SI vs. Control LI p < 0, 05) 
 
 
 
3.3.3. Monocytes 
 
 
• Short Ischemia: BSI, FSI, MSI, CSI 
 
The relative percentage of monocytes within the absolute number of WBC was evaluated with 
CIM in the SI groups. Median and standard deviation values for every time point are expressed 
in %. Due to the reduced percentage of monocytes in relation to the absolute to percentage of 
WBC, the scale in the graphics is limited 50%. BSI and MSI groups showed a statistically 
significant decrease of the percentage of monocytes after time point 0 (p<0,05; Dunn’s test). In 
contrast to this, FSI and CSI presented no significant differences. 
 
 
* 
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Fig. 50: Monocytes -Short Ischemia : Percentage of monocytes in the different study groups after a SI period 
(median and standard deviation are given in %). *Time point vs. Control [Time point 0] (p<0, 05). 
 
• Long Ischemia: BLI, FLI, MLI, CLI 
 
Percentage of monocytes in differential counting of WBC was performed for LI groups. Median 
and standard deviation values for every time point are expressed in %. BLI and MLI groups 
presented a significant decrease of the percentage of monocytes after time point 1. FLI and CLI,  
however, showed no statistically significant differences. 
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Fig. 51: Monocytes-Long Ischemia: percentage of monocytes (CIM) after LI period (median and standard deviation 
are given in %). *Time point vs. Control [Time point 0] (p<0, 05). 
 
Analytical study of the differences between ATG groups and control groups showed no 
significances according to the variable “time of ischemia” while statistical significance was 
obtained for “drug” and “time of perfusion” (p<0.01). Applying Scheffe´s test and using “drug” 
as independent variable, significance was found between the lower values of the ATG groups 
and the higher values of the control groups. Statistical differences between ATG groups and 
control groups were the same in LI groups. However, in SI groups only ATG-Biotest showed 
statistically significant lower values than the control group. 
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Fig. 52: Smoothing-Spline of monocytes: The percentage of monocytes in the three ATG groups was statistically 
lower than the number of WBC in the control group in LI times, while only Biotest-ATG group presented lower 
values in the SI time. (*Control vs. Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG: p<0, 
05). 
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Fig. 53: Smoothing-Spline of monocytes: No statistically significant differences were found according to the length 
of the ischemia times within the study groups. 
 
3.3.4. Microphotographs 
 
The following microphotographs were taken from the analysed CIM slides. Although it is not 
possible to show pictures from all the samples performed due to the place restrictions we think 
they reflect the general behaviour of the groups studied. Note the relative higher number of 
mononuclear cells in the control group when compared to the treated groups and the higher 
number of polymorphonuclear cells present in the study groups. All the microphotographs are 
given as microscope magnifications. 
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1. Biotest Short Ischemia  
 
Fig. 54: Biotest SI group presented a high number of neutrophils in comparison to the other ATG groups. 
Polymorphonuclear cells are shown in the pictures (Fig. 54-A x20, 54-B x100). 
 
 
 
2. Biotest Long Ischemia  
 
 
 
Fig. 55: Biotest LI group presented a high number of neutrophils in comparison to other WBC. Polymorphonuclear 
cells are shown in the pictures (Fig. 55-A x40, 55-B x100). 
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3. Fresenius Short Ischemia 
 
 
 
Fig. 56: Fresenius SI group presented a lower percentage of neutrophils than Biotest-ATG group in CIM. However, 
more neutrophils than other mononuclear cells were observed (Fig. 56-A x20, Fig. 56-B x100). 
 
 
4. Fresenius Long Ischemia 
 
 
 
Fig. 57: Fresenius LI presented more polymorphonuclear cells than mononuclear cells, however, mononuclear cells 
were observed (Fig. 57-A x40, Fig. 57-B x100). 
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5. Merieux Short Ischemia 
 
 
 
Fig. 58: Merieux SI showed, like the other ATG groups, a lower amount of cells in the preparations studied. This 
group also presented more neutrophils than mononuclear cells (Fig. 58-A x40, Fig. 58-B x100). 
 
6. Merieux Long Ischemia 
 
 
 
Fig. 59: MLI group presented a higher amount of polymorphonuclear cells in comparison to other WBC (Fig. 59-A 
x40, 59-B x100). 
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7. Control Short Ischemia 
 
 
Fig. 60: CSI group presented a higher density of cells in the preparation. At the same time, there were more 
mononuclear cells than in the ATG groups, mostly lymphocytes (Fig. 60-A x40, 60-B x100). 
 
 
8. Control Long Ischemia 
 
 
 
Fig. 61: A higher amount of mononuclear cells was also observed in the CLI group. Cellular density was higher 
than in the ATG-groups, as observed in the pictures (Fig. 61-A x20, Fig. 61-B x100) . 
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3.4.Histology and Immunohistochemistry 
 
3.4.1 Results 
Histological and immunohistochemical techniques were performed to assess the muscle damage 
after different times of ischemia and after reperfusion. In addition, samples were analysed for 
leukocyte infiltration in connective, vascular, perivascular and muscular tissue as well as for the 
vascular presence of fibrin.  
Results are expressed as the mean result + standard deviation obtained from the different fields 
studied. The preparations were evaluated randomly and blind. The criteria were arbitrarily 
established although based on previous works in the literature (17, 38, 74, 149):  
• Muscle damage: loss of architecture, necrosis or signs of ischemia were considered: 
- normal architecture: 0 
- light damage: 1 
- moderate damage: 2 
- severe damage: 3 
• Soft tissue infiltration: Connective tissues present in the biopsy as well as connective 
perimisial structures were considered. 
- any WBC in these structures: 1 
- more than 10 cells per field: 2 
- more than 25 cells per field: 3 
• Vascular infiltration: Cells present in the vascular spaces were considered, free or attached to 
the endothelial walls. 
- free cells in the vessels: 1 
- free and attached to the endothelial cells: 2 
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- free cells, attached cells, granulocytes, occluding or almost occluding 
the vessel lumen: 3 
• Perivascular infiltration: Presence of WBC in any tissue adjacent to the vessels: 
- presence of cells attached to endothelial walls: 1 
- presence of cells in perivascular connective tissue: 2 
- presence of cells in perivascular connective tissue and muscular tissue: 
3  
• Muscular infiltration:  
-     no cells in muscle fibres: 0 
- 1-5 cells pro muscular fibre: 1 
- >10 cells pro muscular fibre: 2 
- >25 cells pro muscular fibre: 3  
Results are expressed as the mean values obtained from the different fields studied. The 
preparations were labelled with a code and evaluated blindly. 
 
Fibrin, Masson’s T and CD31 immunostaining were performed to localise fibrin and thrombus 
formation and the criteria were established as follows: 
• Presence of fibrin or thrombocytes in the vascular spaces: 
- presence of fibrin or thrombocytes without occlusion: 1 
- occlusion of the vessel: 2  
- occlusion of the vessel and destruction of the vascular or endothelial 
integrity: 3 
 
The immunoreaction with IL4 was classified as positive or negative depending on the presence 
or absence of this molecule in the sections studied. 
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Muscle damage, connective and muscle tissue infiltration as well as presence of fibrin in the 
vessels are presented in the following table ( table 5). The values are expressed in mean + 
standard deviation. ANOVA was employed to perform the statistical analysis. 
 
CSI FSI BSI MSI CLI FLI BLI MLI  
mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D 
Muscle 
Damage 
 
2,6 
 
0,51 0,9 0,73 
 
1,1 0,73 1,2 0,63 2,8 0,42 1 0,66 1,6 0,69 1,4 0,51
Connect. 
Infiltration 
 
2,5 
 
0,52 1,1 0,31 
 
1,2 0,42 1,3 0,48 2,3 0,67 1,3 0,48 1,4 0,51 1,3 0,48
Vascular 
Infiltration 
 
2,3 
 
0,48 1,1 0,31 
 
1,3 0,48 1,4 0,51 2,4 0,69 1,5 0,52 1,5 0,52 1,3 0,48
Perivasc. 
Infiltration 
 
2,3 
 
0,67 1,2 0,42 
 
1,3 0,48 1,3 0,48 2,3 0,67 1,2 0,42 1,4 0,51 1,5 0,52
Muscular 
Infiltration 
 
2,4 
 
0,69 0,5 0,52 
 
0,4 0,51 0,4 0,51 2,7 0,48 0,4 0,51 0,6 0,51 0,9 0,79
Presence 
Fibrin 
 
1,9 
 
0,56 0,3 0,48 
 
1,2 0,63 0,8 0,63 2,2 0,63 0,8 0,63 1,3 0,67 1,1 0,56
 
Table 5: Histological criteria: Values for Control and ATG groups 
 
These results are also expressed in the following figures to illustrate the differences between the 
studied groups. Morphological differences were typical within the control and ATG groups. 
Control groups´ muscle presented more necrosed fibres, loss of normal muscular tissue 
architecture, areas of haemorrhage and massive and diffuse infiltration of leukocytes in almost 
all the biopsies studied. On the other hand, the ATG groups presented less muscle damage, with 
slight infiltration of the perivascular areas and almost no presence of WBC in the muscular 
tissue. 
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Fig. 62: Muscle damage: ATG groups showed less muscle damage than control groups in short and long ischemia 
times. Biotest groups showed differences between different ischemia times. (*Control Vs. Biotest-ATG; § Control Vs. 
Fresenius-ATG; # Control Vs. Merieux-ATG; $ BSI vs. BLI: p<0,05). 
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Fig. 63: Leukocyte infiltration in the SI  groups 
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Fig. 64: Leukocyte infiltration in the LI groups 
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Fig. 65: ATG groups showed lower infiltration than the control groups for both ischemia times. Fresenius-ATG 
group showed less perivascular and muscular infiltration than the other ATG- groups after LI time. (*Control vs. 
Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG; $, +, FLI vs. BLI and MLI: p<0.05). 
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Fig. 66: Fibrin and CD31+: ATG groups presented lower fibrinoid aggregates and CD-31 positive reaction than 
the control groups for both ischemia times. Fresenius-ATG group and Merieux-ATG group showed more intense 
reaction in LI times. Fresenius-ATG group showed less intense reaction than the other ATG-groups in SI time 
(*Control vs. Biotest-ATG; § Control vs. Fresenius-ATG; # Control vs. Merieux-ATG; $, +, FSI vs. BSI and MSI: 
p<0.05). 
Comparisons within the different groups using the above mentioned criteria presented statistical 
differences on the muscle damage, leukocyte infiltration and presence of fibrin between the ATG 
groups and the control groups. ATG groups showed less muscle damage, leukocyte infiltration 
and vascular presence of fibrin compared to the untreated groups together and taken one by one 
in separate comparisons. Individual comparisons were performed “a posteriori” to detect further 
significances between the groups.  
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All treated groups presented less muscle damage than the control groups. When considering 
ischemia time as independent variable, statistical analysis showed differences only between the 
Biotest groups, with more muscle damage being observed in the LI biopsies. No statistical 
differences in muscle damage were observed within Biotest and Merieux groups both in short 
and long times of ischemia. In contrast to this, Fresenius presents less muscle damage than the 
other ATG groups both in SI and LI times. 
When leukocyte infiltration was analysed according to the explained criteria, ATG groups 
showed statistically significant diminution of infiltration in comparison to the control groups in 
every parameter studied: connective, perivascular, vascular and muscle tissue infiltration both in 
SI and LI times (p<0.05).  
The ATG groups were compared one-by-one to detect differences in the various criteria studied. 
No differences were found between the study groups according to connective and vascular tissue 
infiltration, both in SI and LI times. No differences were found in SI time while studying 
perivascular tissue infiltration. However, Fresenius-ATG groups presented statistically 
significant lower values than the other study groups in perivascular tissue infiltration in the LI 
time (p<0.05). Muscle tissue infiltration presented no significant variances in the SI time groups 
although these differences were present in the LI groups, where the Fresenius-ATG group 
showed less muscle infiltration than the other study groups. 
The differences between study groups treated with the same drug, only varying the ischemia 
time, were studied, these differences only being statistically significant in the case of the 
Merieux-ATG group, with significant higher values of leukocyte infiltration in the LI group. 
Presence of fibrin and activated platelets as well as endothelial cells (CD31+) was studied. 
Control groups showed statistically significant higher values than the study groups both in long 
and short ischemia times (p<0.05). Intragroup differences according to the length of ischemia 
time were only significant in the Fresenius-ATG and Merieux-ATG groups, both presenting 
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higher values of CD31-like immunoreaction and fibrin in the LI groups. After one-to-one 
comparison between the drug groups, Fresenius-ATG group showed statistically significant 
lower values than the other groups in SI time, while no statistically significant differences were 
detected between the study groups within the LI time. 
 
Presence or absence of IL-4 was studied as described before, without considering the different 
ischemia times. Statistical significance between the control groups and the ATG groups was 
detected with student’s t-test. Expression of IL-4 measured by immunohistochemical means was 
significantly higher in the control groups than in the study groups. 
 
Biopsy Control Biotest Fresenius Merieux 
+++ 11/12 1/12 0/12 0/12 
++ 1/12 1/12 1/12 0/12 
+ 0/12 3/12 1/12 1/12 
0 0/12 7/12 10/12 11/12 
 
Table 6: Positive immunoreaction for IL-4 was found mostly in the control group. 
 
 
In the following pages, microphotographs of the control and study groups with the performed 
histological and immunohistochemical techniques will be shown. The pictures will be 
commented after each group of images. All pictures are shown as microscope magnifications.  
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3.4.2. Hematoxiline/Eosin 
3.4.2.1 Control Short Ischemia 
 
Fig. 67:In the control group, massive and diffuse infiltration and inflammation phenomena can be observed. Note 
the extensive infiltration on the picture 67-a. Necrosis and hemorrhagic features as well as tissue infiltration are to 
be seen in the second picture. Infiltration of the connective perivascular tissue is described in the microphotograph 
67-c (arrow). Morphological characteristics of these infiltrates are shown in the picture 67-d. Note: the segmented 
nucleus of the neutrophils adherent to the endothelial cells (67-d, arrow). 
67-a x5 
67-d x40 67-c x20  
67-b x10 
* 
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 3.4.2.2: Biotest Short Ischemia 
 
 
Fig. 68: BSI group presents a well conserved muscular structure and low tissue infiltration. However, the 
aggregation of platelets and fibrin formation in the small vessels is characteristic. These aggregates usually include 
WBC (Fig.68-a). Vessel occlusion is signaled with a * symbol. In the picture 68-d, hemorrhagic phenomena can be 
observed, with extra-vasated erythrocytes in the histological preparation. 
 
 
*
* 
* 
*
68-a x10 68-b x10 
68-c x10 68-d x20 
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 3.4.2.3: Fresenius Short Ischemia 
 
Fig. 69: Lower muscle damage than in the control group was detected in the FSI group. The muscle structure is well 
conserved (69-a, 69-b). However, areas of ischemic tissue can be observed in the external perimeter of some 
muscular fibers (arrows, 69-b). Leukocyte infiltration into connective, vascular, perivascular and muscular tissue is 
slight and comparable to untreated human muscle sections (69-d). Most of the endothelial structures show neither 
loss of structure nor adherence of WBC. (x 10, 20: microscope magnifications) 
 
 
 
 
 
69-a x5 69-b x5 
69-c x20 
69-d x40 
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 3.4.2.4: Merieux Short Ischemia 
 
 
Fig. 70: Biopsies of the Merieux Short Ischemia group present a well defined muscular and vascular structure. Only 
slight damage was found. However, perivascular and vascular infiltration was observed in some of the biopsies, 
showing cellular presence on the connective perivascular tissue (70-c) or included in aggregates on the vascular 
lumen (70-d). Some of the vessels presented accumulation of fibrin or degradation materials without occluding the 
vascular lumina, as shown in the figures 70-c and 70-d. (*, x 10,20 : microscope magnifications) 
 
 
* 
70-a x5 70-b x10 
70-c x20  70-d x20 
*
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3.4.2.5: Control Long Ischemia 
 
Fig. 71: Biopsies obtained from CLI group show massive loss of structure, fiber necrosis and hemorrhagic 
phenomena of muscle. In the picture 71-a, necrosis of muscle fibers can be observed. Infiltration of perimisial tissue 
is shown on the second picture (71-b). Necrosis and ischemic features can be observed at a low magnification on the 
third image (71-c). Please note the diffuse infiltrate present on the muscle surface. The photograph 71-d shows some 
vessels situated between damaged muscle fibers.   
 
 
 
 
 
 
71-d x40 
71-b x20 71-a x5 
71-c x10 
 90
 3.4.2.6: Biotest Long Ischemia 
 
 
Fig. 72: These microphotographs from the BLI group show a well conserved muscle structure  and no muscle 
infiltration (Fig. 72-a, arrows). However, there are WBC present on vascular and perivascular structures (Fig. 72-b 
superior arrow, Fig. 72-c). WBC included in an aggregate adherent to the endothelial wall can be observed in the 
picture 72-b (inferior arrow). Some vessels, mostly venous, present fibrinoid aggregates even occluding the vascular 
lumen, as shown in the picture 72-d (arrow). 
 
 
 
 
 
72-a x10 
72-c x20 
72-b x20 
72-d  x40 
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 3.4.2.7: Fresenius Long Ischemia 
 
 
 
Fig. 73: FLI group presents a well-conserved muscle structure with slight tissue damage (fig. 73-a, 73-b). Necrosis 
is observed in isolated fibers (73-a, arrow). Vascular lumen are not occluded (73-c, 73-d, arrows) and show no or 
slight infiltration or WBC adherent to endothelia (73-c, 73-d). Perivascular and perimisial connective tissue show 
low WBC presence. 
 
 
 
 
 
73-a  x5 73-b  x10 
73-d x40 73-c  x20 
 92
 3.4.2.8: Merieux Long Ischemia 
 
 
 
 
Fig. 74: MLI group shows no leukocyte infiltration in most of the biopsies. The muscular tissue is well structured 
(74-a), although ischemic damage of the muscle is to be seen in some of the histological sections (74-b, §). There is 
slight connective tissue and vascular infiltration in comparison to control groups although presence of WBC in 
some perivascular spaces can be observed (74-d, arrow). MLI presents, however, a higher incidence of fibrinoid 
aggregates in vascular spaces (* 74-b, 74-c) than the SI group of the same drug.  
 
 
 
 
 
74-c x20 74-d x20 
74-a x5 74-b x10 
§ 
* 
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3.4.3 Leukocyte infiltration: Immunohistoreaction to CD45 and granulocyte esterase 
Immunostaining with granulocyte esterase and CD45 is presented in the following 
microphotographs. The upper images correspond to granulocyte esterase while the lower 
represent the CD45 immunoreaction. All pictures are shown as microscope magnifications.  
 3.4.3.1: Control Short Ischemia 
 
Fig. 75: In the upper images, belonging to the CSI group,  perimisial and perivascular presence of neutrophils can 
be observed. PMN aggregates are present on both images. Some neutrophils are present in muscular tissue, as 
shown at a low magnification on the left hand side picture. Positive immunoreaction for CD45 was found in the CSI 
group in all previously defined structures (75-c, 75-d, arrows). On the left hand side, CD45 stained cells can be seen 
in perivascular and connective tissue (arrow). On the right hand side, positive cells adhering to the endothelial wall 
can be observed (arrow). 
75-a x20 75-b x40 
75-c  x40 75-d x40 
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 3.4.3.2: Biotest Short Ischemia 
 
 
Fig. 76: Biopsies from to the BSI group show intravascular presence of neutrophils (76-a, arrow), adhering to the 
endothelial wall in some cases as demonstrated with granulocyte esterase staining e.g. on the picture 76-b (arrow). 
This group shows slight muscular and connective tissue infiltration. Most positive CD45 immunoreactions are found 
in perivascular or vascular spaces (76-d, arrow). 
 
 
76-a x20 76-b x40 
76-d x40 76-c x20 
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 3.4.3.3: Fresenius Short Ischemia 
 
 
Fig. 77: FSI group shows slight presence of neutrophils in muscular and connective tissue (77-a, 77-b). Presence of 
these WBC could be demonstrated in perivascular connective tissue in a very low quantity (Fig. 77-a, arrow). 
Focusing on vascular areas, presence of PMN was much lower than in the control and the other study groups. 
CD45-like immunoreaction was observed in few vascular spaces and could scarcely be detected in muscular tissue 
(77-c, 77-d, arrow). 
 
 
 
 
 
77-a x20 77-b x40 
77-c x20 77-d x40 
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3.4.3.4: Merieux Short Ischemia 
 
 
Fig. 78: Granulocyte esterase reaction for the MSI demonstrated presence of few PMN, mostly localized in 
connective or perivascular areas (78-b, arrow). Some neutrophil aggregates were to be seen attached to the 
vascular wall, as seen on the left hand side picture (78-a, arrow). Positive cells for CD45 were located in the 
vascular spaces, as shown on the right lower picture (78-d, arrows). Muscular and connective tissue showed slight 
other no infiltrates of CD45+ cells. 
 
 
 
78-a x20 78-b x20 
78-c x20 78-d x40 
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3.4.3.5: Control Long Ischemia 
 
Fig. 79: Biopsies of the CLI group show diffuse muscular, connective and perivascular neutrophil infiltration, as 
demonstrated by means of granulocyte esterase staining. In the left hand side picture (Fig. 79-a), many positive cells 
can be observed in these structures. Aggregates of PMN were found attached to the endothelial wall and in the 
perivascular connective tissue (Fig. 79-b, arrow). Positive staining for CD45 was detected in all of the structures 
studied, most of the positive cells being located in perivascular tissue (Fig. 79-c, arrow). However, presence of 
CD45+ cells in connective tissue was also detected (79-d, arrow) in higher amounts than in the study groups. 
 
 
79-a x20 79-b x40 
79-c x40 79-d x40 
 98
3.4.3.6: Biotest Long Ischemia 
 
 
Fig. 80: Positive reaction for granulocyte esterase was found in the BLI mostly in form of aggregates attached to the 
endothelial wall or in the perivascular connective tissue (Fig. 80-b, arrows). However, not all the vessels presented 
such formations, as shown on the left hand side picture (Fig. 80-a, arrow). CD45-like immunoreaction was mostly 
detected in intravascular or adherent WBC aggregates (Fig. 80-d, arrow), showing slight muscle affectation (Fig. 
80-c).  
 
 
 
 
 
80-a x20 
80-c x20 
80-b x40 
80-d x40 
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3.4.3.7: Fresenius Long Ischemia 
 
 
Fig. 81: Positive staining for granulocyte esterase could be observed in the FLI group in the vascular spaces (81-a, 
81-b, arrows). However, the incidence of aggregates attached to the endothelial wall was not as high as in the other 
study groups. Positive CD45 immunoreaction was observed in the same locations (81-c, 81-d, arrows), showing 
slight positive or no reaction at all the muscular structures. 
 
 
 
81-a x20 81-b x40 
81-c x20 81-d x40 
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3.4.3.8: Merieux Long Ischemia 
 
Fig. 82: The biopsies belonging to the MLI groups showed differences when compared to the same drug short 
ischemia group. More PMN positive staining was found, especially in vascular and perivascular spaces (Fig. 82-b, 
arrow). Positive esterase staining was also found in muscular tissue (Fig. 82-a, arrow), although in low quantity. 
Positive immunoreaction for CD45 was found in perivascular and vascular spaces (Fig. 82-c, arrows), as well as in 
connective tissue. However, this fact was not generalized, as most of the vessels showed slight or no infiltration 
(Fig. 82-d). 
 
 
 
 
 
82-a x20 82-b x40 
82-c x20 82-d x20 
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3.4.4: Fibrin, platelets and EC: Weiger`s technique, Masson’s Thrichrome and CD31-
Immunoreaction 
The following microphotographs focus on the vascular structures. The left upper image 
corresponds to Masson’s Thrichromic. The upper right picture corresponds to Weiger`s 
hematoxiline (specific for fibrin). The lower pictures show immunoreaction to CD31 (PECAM).  
 3.4.4.1: Control Short Ischemia 
 
Fig. 83: The upper images from the CSI group show vascular occupation and perivascular loss of structure (83-a, 
83-b, arrows). Masson’s reaction shows a damaged muscle with extended areas of haemorrhage (83-a, *). CD31 
immunoreaction shows positive staining on endothelia with activated thrombocyte aggregates in the vascular lumen 
and adherence to the endothelial wall (83-c, 83-d, arrows). 
83-a x20 83-b x40 
83-c x20 83-d x40 
* 
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3.4.4.2: Biotest Short Ischemia 
 
Fig. 84: BSI group shows presence of fibrinoid aggregates in the small vessels, as can be seen in the two upper 
pictures (84-a, 84-b). However, the muscle is well structured and no signs of ischemia or necrosis are observed. In 
the lower pictures, CD31-like positive immunoreaction is detected in endothelia ( 84-c, arrow) and in small cellular 
aggregates adherent to the endothelial wall of small vessels (84-d, arrow). 
 
 
 
 
 
 
84-a x10 84-b x10 
84-c x20 84-d x40 
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 3.4.4.3: Fresenius Short Ischemia 
 
 
Fig. 85: The vessels belonging to the FSI group are well conserved. None or few fibrinoid aggregates are seen in 
the vascular spaces with Masson’s Thrichrome technique (Fig. 85-a, arrow). However, presence of fibrin between 
the muscle fibers was detected in low quantity (Fig. 85-b, arrow). Positive immunoreaction for CD31 was weak 
(Fig. 85-c) and limited to endothelia (Fig. 85-d, arrow).Few  positive intravascular or perivascular cell aggregates 
including activated thrombocytes were observed.   
 
 
 
 
 
85-a x20    85-b x10 
85-c x20 85-d x40 
 104
3.4.4.4: Merieux Short Ischemia 
 
 
Fig. 86: MSI group demonstrated low presence of fibrinoid aggregates in perimisial and intramuscular vascular 
spaces. Most of the positive reactions were found in the perimisial or endomisial connective tissue vessels (Fig. 86-
a, arrow). Positive reaction for the Weiger`s technique was also observed in the connective tissue adjacent to the 
muscle fibers (Fig. 86-b, arrow). CD31-like immunoreaction was detected in vascular endothelia (Figs. 86-c, 86-d), 
showing no presence of positive reactions in the vascular lumina or thrombocyte aggregates. 
 
 
 
86-a x20 
86-c x20 
86-b x20 
86-d x40 
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 3.4.4.5: Control Long Ischemia 
 
Fig. 87: CLI group biopsies’ analysis with conventional techniques showed diffuse muscle damage and 
haemorrhage, presence of huge fibrinoid aggregates in the vascular spaces and general muscle damage (Figs. 87-a, 
87-b, arrows, *). Positive immunoreaction for CD31 was observed both in endothelia and in adherent cells (Fig. 87-
c, arrow). Intravascular aggregates showing positive immunoreaction could also be seen (Fig. 87-d, arrow)  
 
 
 
 
87-a x20 87-b x40 
87-c x20 87-d x40 
* 
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 3.4.4.6: Biotest Long Ischemia 
 
Fig. 88: Presence of fibrinoid structures and positive reaction for fibrin were demonstrated in vascular spaces of the 
BLI group. However, these findings were not present in all the vessels. On the upper left hand side, a small 
accumulation of cells in the vascular lumen can be observed (Fig. 88-a, arrow). On the right hand side, a fibrin 
aggregate with cells included is shown (Fig. 88-b, arrow). CD31 immunostaining showed the same phenomena as 
the non-specific techniques. In both pictures the presence of CD31-positive aggregates and cells can be observed 
(Figs. 88-c, 88-d, arrows). 
 
 
 
88-a x20 88-b x40 
88-c x20 88-d x40 
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 3.4.4.7: Fresenius Long Ischemia 
 
Fig. 89: FLI group shows low presence of fibrinoid aggregates in the small vessels, the bigger vessels being 
permeable, as can be seen in the left upper picture (Fig. 89-a, arrow). Furthermore, the muscle is well structured 
and little presence of fibrin is observed (Fig. 89-b, arrow). In the lower pictures, CD31-like positive 
immunoreaction is detected in endothelia as well as in cellular aggregates adherent to the endothelial wall of small 
vessels (89-c, 89-d, arrows). 
 
 
 
 
89-a x20 89-b x10 
89-c x20 89-d x40 
*
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3.4.4.8: Merieux Long Ischemia 
 
Fig. 90: Masson’s Thrichrome shows fibrinoid or cellular aggregates present in the vascular lumina of the Merieux 
long ischemia group (Fig. 90-a, arrow). Fibrinoid structures are observed in the perivascular space (Fig. 90-b, 
arrow). This fact is confirmed by the CD31 immunostaining, as shown in the lower pictures (90-c, 90-d arrows) 
were cellular aggregates show positivity for CD31, thus demonstrating the existence of thrombocytes on these 
structures.  
 
 
 
 
 
90-a x20 90-b x20 
90-c x20 90-d x40 
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3.4.5: IL-4 Immunoreaction 
 
 3.4.5.1: Control Group 
 
 
Fig. 91: Positive immunoreaction for the monoclonal antibody anti-IL-4 was found in the control groups in 
connective, vascular and muscular structures (Figs. 91-a,-b,-c,-d). In the upper left picture, stained cells in all these 
structures are shown (Fig. 91-a, arrows). Endothelial expression of IL-4 is shown in the right upper picture (Fig. 
91-b, arrows). The cellular expression of IL-4, surrounding a WBC (Fig. 91-c, arrow) or between two WBC in the 
figure 91-d can be observed in the lower pictures at a higher magnification. 
91-a x20 
91-c. x40 
91-b x40 
91-d x100 
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 3.4.5.2. Study groups and negative control of the technique 
 
Fig. 92: No or low immunoreaction was observed in the study groups. We can observe in the pictures that the 
muscle and connective tissues are free from positive staining for IL-4 (92-a,-b,-c). However, as can be seen in the 
left upper picture, there are cells showing immunoreaction for IL-4 in muscular tissue in the Biotest-ATG group 
(Fig. 92-a, arrows). The right bottom picture is a negative control of the technique, performed by substituting the 
primary antibody for PBS (Fig. 92-d). 
 
 
 
 
 
 
 
 
 
92-a x20 
92-c  x20 
92-b x20 
92-d x20 
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4. DISCUSSION 
 
4.1. Discussion of material and methods 
 
4.1.1 Ischemia-Reperfusion Injury and Transplantation 
Organ, tissue and cell transplantation has achieved impressive results in the last three decades as 
a treatment modality for patients with end-stage organ diseases (148). Since the first successful 
heart transplantation (11) in Cape-Town took place, transplantation was thought to be the easiest 
solution to improve the life quality of many patients as well as the key to life’s prolongation. 
However, it was not easy to achieve the actual status in this field. First, this achievement can be 
attributed to the development of advanced technical skills and technological means. Advances in 
surgical technique have improved the recovery time of the patients (60, 186, 202), decreased the 
mortality in those surgical procedures (106), treated congenital end-stage diseases at low ages 
(138, 189), diminished the use of long-term medical devices such as dialysis thus improving life 
quality. Second, the development of immunosuppressive agents has considerably reduced the 
number of organ rejections and subsequent transplantation failure (177) as well as controlled the 
incidence of graft vs. host disease (179). This development is related to research in 
transplantation immunobiology, which has much improved our understanding of the alloimmune 
response and the complex mechanisms undergoing cell and cytokine interaction (148). However, 
other problems are still to be solved and among them is ischemia/reperfusion injury. 
In organ transplantation, IRI is a multifactorial process that leads to organ damage and primary 
graft dysfunction (82). Cessation of blood flow deprives the cell and subsequently the grafted 
organ of energy metabolism and appropriate activity. Different mechanisms are implied in IRI 
such as macrophage and leukocyte interactions, microcirculatory changes, release of oxygen-
derived free radicals, nitric oxide and calcium metabolism, endothelial cell molecules and 
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inflammatory mediators. There is little question about IRI importance upon transplantation 
processes and multiple studies to investigate all these molecular and cellular events associated to 
the deleterious effects of IRI are being carried out.  
 
4.1.2 Polyclonal antibodies 
 
Multiple strategies have been designed to avoid or lessen the cellular and tissue derangements 
produced after reperfusion. Use of immunosuppressive agents such as Tacrolimus (182, 212), 
Rapamycin (159), Cyclosporine (107, 132, 159), anti-CD11 monoclonal antibodies (155) and 
OKT3 (178) have been suggested. Antibodies blocking other molecules present in IRI have been 
employed, e.g. anti-endothelin receptor (147), adenosine (121), different antibodies anti-adhesion 
molecules, complement and  activating factors (123, 136), anti- oxygen-derived free radicals or 
arachidonic acid inhibitor (16, 170), calcium-channels blocker (48), allopurinol and superoxid 
dismutase (68), etc. Physical methods have been suggested as possible strategies to block IRI, 
among them leukocyte depletion pre-reperfusion (105, 175), changes of perfusion times and 
temperature (143), or different preservation and storage solutions (84, 110, 172). Organ or tissue 
preconditioning with different methods has also been performed by means of heat (119), gas 
(167) or drugs (208). Gene therapy against certain activation molecules and endothelial 
compounds of the reperfusion process has been developed without definitive results (54, 81, 
154). As the number of immunosuppressive agents increases, the election of the correct agents 
for a precise therapy becomes more difficult. This is one of the reasons why the mechanism of 
these different drugs and their effect on the immune cells must be accurately studied and 
described. Polyclonal ATGs are antibody preparations obtained by immunization of horses or 
rabbits with human lymphocytes from definite cell lines (8) or suspended human thymocytes 
(193, 198) and with a wide clinical application. The mechanism by which polyclonal 
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antilymphocyte preparations suppress immune responses is not fully understood, but T-cell 
depletion and immune modulation on a molecular level are included (166, 211). ATGs contain a 
variety of antibodies recognizing key receptors on T-cells, being able to inactivate or kill them, 
thus reversing the rejection process.  
ATGs have been and, in some cases, still are used in the clinical practice in a broad spectrum of 
therapeutical activities in different fields. One of the most important is transplantation. 
Polyclonal ATGs have been employed as induction therapy (28, 75, 137, 207), concomitant 
immunosupression (29, 76, 79), treatment of graft vs. host disease (34, 76, 161), acute rejection 
therapy (18, 26, 152). They have been employed in aplastic anaemia (199, 201), treatment of 
autoimmune diseases, such as lupus (130) or rheumatoid arthritis (192) and skin diseases, e.g. 
cutaneous lymphoma (43) or contact allergy (174). These drugs cause, however, a wide range of 
adverse reactions, which sometimes superpose the possible benefit of their administration. The 
most common are cardiopulmonary reactions (108), fever (94), elevation of TNF-α in plasma 
(39), concomitant infection with CMV (98, 180, 204), hypersensitivity to rabbit or horse proteins 
(158) or serum sickness with cutaneous manifestations (36). 
To our knowledge, this is the first time that the effect of pATGs upon IRI has been investigated. 
Our choice was based on the wide range of cellular and molecular effects explained in the 
introduction of this work which could have an influence on the establishment and development 
of IRI and its associated features. It is also, to our knowledge, the first time that the three existing 
polyclonal antibodies on the German market, Fresenius-ATG © (Fresenius, Bad Homburg, 
Germany), Tecelac© (Biotest Pharma GmbH, Dreieich, Germany) and Thymoglobuline©(Imtix-
Sangstat California, USA)],  are compared with each other. 
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4.1.3 The animal model 
 
Transplantation and xenotransplantation experiments can be performed either by experimental 
organ or tissue transplantation or by using artificial perfusion systems where donor organs can be 
perfused with allogeneic blood, xenogeneic blood or blood components (59, 142). Ex vivo 
perfusion of an organ or a tissue with a perfusion system is valuable in establishing the relative 
value of the factors involved in the rejection process. Several models have been designed to 
perfuse isolated organs with allogeneic or xenogeneic blood ex-vivo to investigate not only 
inflammation (140) or rejection phenomena (206), but also interactions between different drugs 
and vascular endothelia (25) or tissue response to definite antigens (90). Pascher et al. (145) 
defined a suitable model for perfusing isolated organs simulating the normal physiological 
conditions. In these systems the organ is isolated and connected to an artificial circulatory circuit 
to perfuse it at physiologic pressure, normothermia and oxygenation conditions (50, 145). 
Furthermore, these models allow obtaining tissue specimens for histopathological studies, 
measurement of functional parameters, the test of different drugs as potential therapeutic agents 
for IRI or acute rejection (59). Perfusion of isolated limbs is considered an ex-vivo perfusion 
model, as no systemic interactions are present after the access to general blood circulation is 
avoided. 
Our model was designed to study the interactions between antithymocyte globulins (ATG) and 
cells or tissues during ischemia reperfusion injury, to assess the potential effect of these drugs as 
therapeutical agents in IRI. These polyclonal antibodies are directed against human cells; 
therefore the experiments had to be performed using human blood. However, this experimental 
set-up cannot be applied to humans, both due to ethical and legal reasons. To test these 
polyclonal antibodies under in vivo condition, a model of perfusion in non-human primates was 
designed, although there are legal restrictions on performing research with primates. The ethical 
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issues are much more complicated than in research with other animal species due to the 
behavioural similarities of men and these primates and the pressure of certain anti-animal-
research groups. Our choice of non-human primates is related to the similarities of the non-
human primate endothelia with human endothelia (80, 210) and thus the possibility of obtaining 
comparable and clinically valid cell interactions when these vessels were perfused with human 
blood of the corresponding blood group. Although our model can be criticized for employing 
two different species, immunological concordance, morphological vascular similarities and the 
impossibility of other in vivo experiments to test the effect of ATGs in IRI may still allow us to 
extract valid conclusions from our results.  
Perfusion of isolated limbs is extensively used in the literature as a valid model to test different 
drugs without affecting the systemic circulation (45, 50, 196). Our model is designed to evaluate 
the results obtained in the capillary superficial net of muscle vessels and to extrapolate it to the 
microcirculation of sinusoidal organs. That is because, due to its functional similarities (10, 209), 
superficial circulation of the extremities, especially upper muscle and dermis, reproduces the 
capillary circulation of most of the solid organs. Our technical set-up has also been extensively 
discussed, demonstrating no cell activation or damage as well as no cellular interactions during 
the process of reperfusion (144). 
 
 
4.1.4 Evaluation of the results 
 
To evaluate the results obtained, different methods and techniques were applied. The number of 
blood cells and other blood parameters in PB were counted to monitor the state of the animal 
during the surgical procedure and the reperfusion process. The number of WBC was studied to 
assess the cytotoxicity of the three different ATGs applied to PB. The number of RBC and 
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platelets were also measured to differentiate a possible toxic effect of the employed drugs. These 
methods have been extensively described in the literature to evaluate the immunological and 
macrohaemodynamic situation of patients during (3, 49) and after transplantation (164, 191), or 
animals during research procedures (42). 
Peripheral blood smears are of current use in some clinical procedures, such as haematological 
and oncologic diagnostic (9). Blood smears were also performed to examine the state of the 
various cell subpopulations in peripheral blood and to test the toxicity of certain drugs or 
procedures. We have used this cytological tool for various reasons. First of all it was our 
objective to correlate the morphological findings with the cell numbers obtained in the PB 
counting. A second reason was to investigate possible erythrocyte malformations due to the 
cytotoxic effect of ATGs. Another reason was to assess the cellular variation of the different 
WBC subpopulations in answer to IRI and the three different drugs employed and to compare 
them.  
Cyto-immunological monitoring is a non invasive tool used in the clinic and in experimental 
research allowing one to differentiate the various subpopulations of lymphocytes and their 
activated forms (63). This tool has a special importance because it permits one to distinguish 
between different inflammatory events. With CIM we studied the behaviour of the different 
subpopulations of WBC isolated from peripheral blood. It allowed monitoring the activation of 
WBC and the relationship between the different cell subpopulations during the reperfusion injury 
and with the three different immunosuppressive agents employed. CIM has been used in 
experimental procedures to investigate the extent of acute rejection, graft damage or infection 
and other inflammatory processes (64, 92, 176, 188). 
Routine histological techniques such as staining with haematoxylin-eosin or Masson’s 
Thrichrome are usually performed in experimental and clinical procedures to evaluate the extent 
of histological lesions, the intensity of tissue inflammation, tissue damage or leukocyte 
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infiltration (46, 117, 197). They can also be employed to detect fibrosis in the vascular bed or 
presence of fibrinoid aggregates (6, 13, 93). We used haematoxylin-eosin, Masson’s  thrichromic 
and Weiger’s haematoxylin staining to investigate the general state of the reperfused muscle, the 
extent of leukocyte infiltration and muscle damage as well as fibrosis, necrosis or thrombosis 
phenomena. 
Leukocyte infiltration, inflammatory mediators and neutrophil-mediated tissue injury are 
important factors in the development and latter consequences of IRI. These cellular factors were 
studied by means of immunohistochemical methods. All of them play an important role during 
IRI as CD45 (LCA) shows positive reactions to WBC and granulocyte esterase is also expressed 
on neutrophils. CD31 (PECAM) is an adhesion molecule leading leukocytes to adhesion through 
endothelial and platelet activation. Stainings with CD45, CD31 and granulocyte esterase were 
performed in our experiments to evaluate the presence of WBC in different tissues, activation of 
platelets leading to leukocyte adhesion and neutrophil-mediated cytotoxicity. These techniques 
have often been employed not only in the study of IRI but also in other inflammatory events (47, 
61, 67, 139). 
IL-4 is a central cytokine involved in the development of inflammation and in the regulation of 
the cooperating T-lymphocyte response (205). T helper lymphocytes play an important role in 
IRI as they are able to activate other WBC subpopulations such as NK cells or macrophages 
(57). We investigated the effect of ATGs on the expression and release of IL-4 by 
immunohistochemical means and correlated these results with tissue damage and further cell 
activation. 
The evaluation of the histological and immunohistochemical staining was scored by two 
independent observers. Minor difference on the scoring was resolved by agreement. Semi-
quantitative analysis was performed and the results classified according to previously established 
criteria that graded the muscle damage, leukocyte infiltration, vascular damage and the 
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presence/absence of IL-4. These evaluation methods are accepted in the literature (38, 95) as a 
reliable tool for studying tissue damage and morphological changes in rejection and IRI. 
The statistical evaluation of the results was performed by means of different statistical 
techniques. Descriptive statistics were presented by median + standard deviation, a method 
commonly used in the literature (184). Analytical study of the groups by means of ANOVA is 
recommended to compare different groups and permitted us to investigate the effect of taking 
different variables as dependent or independent. Scheffe´s correction is one of the methods 
employed to correct the global results of ANOVA when comparing groups one-by-one. Our 
choice to use nonparametric function estimation with stochastic data or smoothing-spline as a 
method to design a multivariate model for each group is due to the versatile behaviour of these 
models and their fair correlation with the analytical study of the groups. 
Analysis of several study groups with dependent and independent variables as well as correction 
of the results and construction of multivariate models are well-established methods for 
scientifical statistical analysis (32, 184).  
 
4.2 Discussion of the results 
 
4.2.1 Influence of ATG on peripheral blood counts 
 
The absolute number of circulating WBC during the reperfusion was reduced in the ATG groups 
when compared to the control group. Our results are in agreement with other clinical and 
experimental studies. This reduction may be related to the lymphocytotoxicity of these 
polyclonal antibodies (156) and at the same time to the higher induction of apoptosis of 
peripheral lymphocytes through CD95 ligand (52, 53). When comparing the groups one-by-one, 
only the Merieux-ATG group showed a lower number of peripheral WBC in short ischemia, 
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suggesting a reduction of the lymphocytotoxic activity parallel to the increase of the ischemia 
time. No data supporting or negating this fact have been found in the literature.  
With respect to RBC, the ATG groups present higher values of circulating erythrocytes in 
comparison to the control group. This reduction of circulating RBC may be due to the presence 
of haemorrhage and muscle damage in the control groups during the reperfusion and also to the 
increased number of thrombi or fibrinoid aggregates present in the vessels and the capillary net 
of the control groups compared to the treated groups.  
These facts, higher incidence of haemorrhage, muscle damage and higher presence of fibrin, 
thrombi and fibrinoid aggregates in the control groups may, in the same way, be related to the 
increased values of RBC, haemoglobin and haematocrit presented by the ATG groups in 
comparison to the control groups. In fact, although the haematocrit was set in 30% to enable a 
better circulation through the perfusion system, all blood related parameters suffered a parallel 
decrease in the control groups, significantly more severe than the decrease of the ATG groups.  
The number of circulating thrombocytes had a particular behaviour that may be separately 
discussed. The number of thrombocytes in the control groups was already higher at the 
beginning of the reperfusion when compared to the ATG groups. This fact suggests a relative 
toxicity of ATGs to platelets, a conclusoin supported by the property of ATGs to recognize 
antigens expressed in non-lymphoid cells (platelets, endothelium, etc.) as shown by Bonnefoy-
Berard et al (21). During the following reperfusion process, the values of platelets in the 
Fresenius-ATG groups decreased parallel to the control groups while the number of circulating 
thrombocytes in the Merieux-ATG and Biotest-ATG groups decreased significantly. This finding 
may be related to the different origin of the three ATGs: both Merieux and Biotest ATGs 
deriving from human thymocytes, Fresenius from a cultured Jurkat cell line. However, no 
previous investigation to support these theories was found in the literature. A further 
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investigation to test in vitro toxic properties of ATGs against blood components is 
recommended.  
 
4.2.2 Influence of ATG on peripheral blood smears 
 
Blood smears were performed to evaluate the behaviour of the different WBC subpopulations in 
whole blood both for the control and the ATG groups as well as to test the influence of ATGs on 
the different types of WBC after a period of ischemia and later reperfusion.  
A significant decrease of the number of lymphocytes in the ATG groups in comparison to the 
control groups both in SI and LI times is observed. This finding shows a good correlation 
between the morpho-cytological study and the counts obtained from PB. Diminution of 
lymphocytes was constant for all the ATG groups, but showing significant differences between 
them, probably related to lymphocytotoxicity and apoptosis induction of ATGs for this WBC 
subpopulation. There is, however, a significant difference in the Merieux-ATG group according 
to the “time of ischemia” variable. In the PB counts, the number of WBC in the LI group was 
higher than in the SI group, while in the blood smears the percentage of lymphocytes was higher 
in the SI group. In our opinion, the relative increase of WBC in peripheral blood of the long 
ischemia group is related to the increase of neutrophils, having no direct relation with the 
percentage of lymphocyte in the preparation. 
The percentage of neutrophils in PB counted in whole blood smears showed a significant 
difference between control and study groups. The percentage of neutrophils is significantly 
higher in the ATG groups than in the control groups although the number of circulating WBC is 
lower. This may be explained by the lymphocyte depleting activity of ATGs. The number of 
circulating WBC is fundamentally reduced due to the lymphocyte depletion. Therefore there is a 
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reduction of the percentage of lymphocytes and consequently a higher percentage of neutrophils 
in the extensions.  
The same occurs when studying the percentage of monocytes, although in this case, the 
percentage of these cells does not change significantly during the reperfusion. 
In the microphotographs presented, the presence of mononuclear cells is much higher in the 
control groups than in the ATG groups both in SI and LI times. In the latter, one finds more 
polymorphonuclear cells. That is consistent with the results shown and the relative increase of 
PMN in the ATG groups due to the lymphocytotoxic properties of these drugs. Occasional 
presence of damaged erythrocytes was documented although it had no relation to the drug 
employed or the time of ischemia. 
 
4.2.3 Influence of ATGs on WBC subpopulations  
 
Cyto-immunomonitoring has been used to study inflammatory events in the field of 
transplantation, as explained before. With the help of this technique we studied the influence of 
the ATGs upon the behaviour of the different WBC subpopulations. These data are also shown in 
percentage, meaning that the values of the different subgroups of cells are relative to the total of 
WBC in the cytological preparation. CIM results are consistent with the percentages of WBC 
shown in whole blood and blood smears. The percentage of lymphocytes in CIM was 
significantly lower in the ATG groups than in the control groups. This is explained by the direct 
lymphotoxicity of ATGs and the increased rate of apoptosis in this cell subpopulation. No 
differences were found related to ischemia time in this part of the study.  
Neutrophil and monocyte percentages also presented a parallel behaviour to the whole blood 
smears and were higher in the ATG groups than in the control groups. However, the Biotest-
ATG group presented lower values of neutrophils when compared to the Fresenius-ATG group 
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in the SI time and lower values than the other groups in the percentage of monocytes also in the 
SI time. This may be explained by the presence of eosinophils and LGLs in some of the samples 
of the Biotest-ATG group which are not shown although counted, perhaps modifying the 
percentage of neutrophils and monocytes. 
The microphotographs revealed a higher presence of PMN in the ATG groups. The nuclear 
modifications of these cells suggest regeneration of this cell subpopulation after cellular damage. 
The nuclei of the PMN are hypersegmented and these cells show in some ATG groups’ 
membranous damage. A higher presence of mononuclear cells is observed in the control groups 
during the reperfusion.  
 
4.2.4 Influence of ATGs on tissue, vascular damage and leukocyte infiltration  
 
All groups treated with one of the three different ATGs presented less muscle damage than the 
control groups. The differences were statistically significant. As could be observed in the 
microphotographs shown, the tissue samples of the control groups presented a high rate of fibre 
necrosis, wide areas of haemorrhage and areas of diffuse infiltration throughout the muscular and 
connective tissue. Biochemical features such as release of OFR or proinflammatory cytokines 
and cellular features such as neutrophils and endothelial cell activation are mainly responsible 
for this muscle damage and loss of structure (96). Focusing on the cellular features, the presence 
of infiltrating neutrophils and other WBC such as lymphocytes or macrophages in tissue was due 
to an increase in the release of proinflammatory mediators and adhesion molecules provoked by 
the activation of endothelial cells after reperfusion (35). This cellular activity may be decreased 
by ATGs, as no comparable muscle damage was observed on the ATG groups.  
The muscle damage observed has a tight relationship to the extent of the leukocyte infiltration in 
muscular, vascular, connective perivascular and perimisial tissue. Decrease of leukocyte 
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infiltration was observed by immunohistochemical staining with CD45 and granulocyte esterase 
in all the ATG groups in comparison to the control groups. Differences between the ATG groups 
were restricted to the LI time. After LI, the Fresenius-ATG group showed less muscle and 
perivascular tissue infiltration in one-by-one comparison with the other two ATG groups. These 
differences were not found in connective or vascular infiltration according to the study criteria. 
Merieux-ATG groups showed more general infiltration after LI than after SI, consistent with the 
previously explained results for PB counts and blood smears. These differences may be related to 
the different origin of the three ATGs. 
WBC presence in tissue after reperfusion is directly related to increased neutrophil adhesion and 
activation of immune and endothelial cells (165). Although the exact nature of interactions 
between endothelial and cellular adhesion molecules has not been clearly defined, a decrease of 
WBCs present in muscle and muscular vessels as well as a reduction in the number of infiltrating 
neutrophils in the same area suggest that ATG may play a role in blocking the process of 
transendothelial leukocyte migration. This anti-inflammatory action might be due to the 
lymphocyte depletion and subsequent decrease of the activation of endothelial cells after 
reperfusion or might be related to a direct effect on adhesion molecules and proinflammatory 
mediators. Both hypotheses are partially supported by our data, as less endothelial or vascular 
damage is strongly associated to a diminution of the circulating WBC observed in PB counts, 
smears and CIM and to a decrease of the extent of tissue infiltration. However, decrease of CD-
31 and IL-4 expression also partially supports the direct blocking of adhesion molecules and 
proinflammatory cytokines. In any case, further experiments must be performed to define the 
exact mechanism of action of ATGs in preventing leukocyte transendothelial migration and 
subsequent muscle damage after reperfusion. 
 Vascular obliteration related to fibrin or fibrinoid aggregate formation as well as to endothelial 
and thrombocyte activation was measured by means of histological (Masson’s Thrichrome, 
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Weiger`s Haematoxylin) and immunohistochemical (CD31) techniques. Control groups showed 
more presence of fibrin and positive reaction for CD31 than the ATG groups. Activated 
thrombocytes adhered to the endothelial cells or were included in vascular aggregates. They were 
observed in most of the biopsies studied both in SI and LI. ATG groups, however, showed a 
lower presence of positive reaction for CD31 and fibrin staining as compared to the control 
groups. The intragroup differences observed for the ATG groups may be related to the different 
origin of the three ATGs.  
Decrease of the positive reaction for CD31 (PECAM) can explain the diminution of the 
transendothelial leukocyte migration, as CD31 is one of the most important adhesion molecules 
implied in this process (35, 58). In fact, many publications assert that decrease of the expression 
of PECAM attenuates reperfusion injury (30, 47) and ameliorates the outcome of the reperfused 
tissue (89). This fact supports the hypothesis that ATGs have a protective effect upon IRI by 
direct blocking adhesion molecules or by diminution of the production of these molecules as a 
consequence of leukocyte depletion.  
Cellular inflammation and infiltrating WBC in tissue also lead to muscle damage. Demonstration 
of IL-4 in our model is related to a higher WBC presence and greater muscle damage. This fact 
may be related to a participation of IL-4 in the proinflammatory cascade accompanying IRI as an 
activator of Th2 helper lymphocytes. Therefore, inhibition of IL-4 release might result in a 
decrease of the cooperation between lymphocytes, decrease of other inflammation molecules 
such as TNF-α or IL-2  and subsequently less endothelial activation and vascular damage (44, 
162). ATG groups show in our model significantly less presence of IL-4 than the control groups. 
These results are consistent with the hypothesis that IL-4 release may have a proinflammatory 
role in muscle ischemia reperfusion injury. 
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5- SUMMARY AND CONCLUSIONS 
 
Background:  
Ischemia-reperfusion injury (IRI) is a non-specific, antigen independent event, which 
significantly influences the outcome of transplanted organs. Anti-thymocyte globulins (ATGs) 
are used to prevent acute rejection after transplantation, to induce immunosuppression and to 
overcome graft vs. host disease or haematological disorders. ATGs induce apoptosis and 
complement-mediated cell death in peripheral T-lymphocytes and have the potential to inhibit 
leukocyte adhesion by directly binding to adhesion molecules. We analysed, by means of 
cytology, histology and Immunohistochemistry, the microvasculature and the different blood 
cell-subpopulations upon ischemia/reperfusion after induction of immunosupression by three 
different ATGs.  
 
Material and Methods: 
Extremities of cynomolgus monkeys were flushed with Ringer’s lactate solution at 4 C° via 
either the femoral or the brachial artery. After 60 minutes of ischemia the limbs were reperfused 
with human blood of the corresponding blood group (BG 0). ATGs were added to the blood, 
diluted to a haematocrit of 30 % with Krebs-Henseleit-buffer, 20 min prior to the reperfusion.  
Perfusion was carried out in a re-circulatory perfusion system. The limbs (n=60) were assigned 
to four groups: Biotest-ATG group (n=20), Fresenius-ATG group (n=12), Merieux-ATG (n=11) 
and control group (without ATG; n=17). The perfused muscle was investigated using intravital 
microscopy to determine the influence of ATGs on the microcirculation. Monitoring of 
haematological parameters was performed and counts of RBC, WBC, platelets, haematocrit and 
haemoglobin were realised. Cytology and Cyto-immunological-monitoring (CIM) were 
performed in blood samples taken at different time points (0,1,5,10,15,30,45 and 60 min) after 
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onset of reperfusion. Biopsies from muscular tissue were taken after the experiments. 
Histological and immunohistochemical techniques were used to investigate the vascular damage 
and the distribution of WBC in vascular, perivascular and muscular tissue, applying semi-
quantitative analysis to evaluate the results. 
 
Results and conclusions: 
The following conclusions may be drawn from the results: 
• Monitoring of the haematological parameters showed a decrease in the number of WBC 
in the treated groups compared to the control groups. The amount of RBC, haemoglobin 
and the haematocrit was significantly higher in the treated groups than in the control 
groups. 
• ATG-Biotest and Merieux-ATG groups showed a decrease in the number of circulating 
platelets in comparison to Fresenius-ATG and control groups. 
• Cytological and CIM studies demonstrated significant differences in lymphocytotoxicity 
and depletion of peripheral lymphocytes in the ATG groups in comparison to the control 
groups.  
• Histological and immunohistochemical analyses showed a decrease in vascular and 
perivascular infiltration as well as muscle inflammatory reactions after ATGs treatment.  
• Expression of IL-4 was reduced in the ATG groups when compared to the control group. 
• ATGs influence IRI, having a positive effect on the outcome of reperfused tissues  
 
.  
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6- ZUSAMMENFASSUNG 
 
Hintergrund: 
Der Ischämie-Reperfusionsschaden ist ein unspezifischer, Antigen unabhängiger 
pathophysiologischer Prozess, welcher bedeutenden Einfluß auf das Überleben transplantierter 
Organe hat. Antithymozyten-Globuline (ATGs) werden als Immunsuppressiva in der Therapie 
akuter Abstoßungsepisoden und zur Unterdrückung der Graft vs Host Disease sowie 
hämatologischer Funktionsstörungen eingesetzt. ATGs führen zu Apoptose und Komplement 
vermitteltem Zelltod, wobei die direkte Bindung an Adhäsionsmoleküle die Leukozyten-
Adhäsion hemmt.  
Wir haben mittels Zytologie, Histologie und Immunhistochemie den Einfluß dreier 
verschiedener ATGs auf die Mikrozirkulation sowie die unterschiedlichen Zellsubpopulationen 
nach Ischämie/Reperfusion untersucht. 
 
Material und Methoden: 
Arterie und Vene der Extremitäten von Affen (M. fascicularis) wurden isoliert, mit 4 C° kalter 
Ringer-Laktatlösung gespült und nach einer Ischämiezeit von einer bzw. zwei Stunden über die 
femorale bzw. brachiale Arterie mit Blutgruppen-kompatiblen Humanblut reperfundiert. 
Dem mit Krebs-Henseleit-Puffer auf einen Hämatokrit von 30% verdünntem Blut wurden ATGs 
20 Minuten vor der Reperfusion zugefügt. Die Perfusion wurde mit Hilfe eines 
Perfusionssystems rezirkulierend durchgeführt. Die Extremitäten (n=60) wurden entsprechend 
dem Versuchsansatz vier verschiedenen Gruppen zugeteilt: Biotest-ATG Gruppe (n=16), 
Fresenius-ATG Gruppe (n=16), Merieux-ATG Gruppe (n=12) und eine Kontroll-Gruppe (ohne 
ATG; n=16). Während der Perfusion wurde die Mikrozirkulation der perfundierten Muskulatur 
mittels Intravital-Mikroskopie untersucht. Neben der Bestimmung hämatologischer Parameter, 
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wurden die Anzahl der Rot Blutzellen (RBZ), weiß Blutzellen (WBK), Thrombozyten sowie die 
Hämatokrit- und Hämoglobinspiegel im Perfusat zu verschiedenen Zeitpunkten bestimmt. 
Zytologische Untersuchungen und zyto-immunologisches Monitoring (CIM) wurde in 
Blutproben, welche zu unterschiedlichen Zeitpunkten (0,1,5,10,15,30,45,60 Min.) abgenommen 
wurden, durchgeführt. 
Nach den Versuchen wurden Biopsien von Muskelgewebe entnommen. Histologische und 
immunhistologische Techniken wurden angewandt, um den Einfluß der ATGs auf die Integrität 
des Gewebes und die Infiltration der weißen Blutzellen (WBZ) im vaskulären, perivaskulären 
und muskulären Gewebe semi-quantitativ zu analysieren. 
 
Ergebnisse und Folgerungen: 
• Die hämatologische Untersuchung ergab eine signifikante Reduktion der zirkulierenden 
WBZ in den behandelten Gruppen im Vergleich zu der Kontrolle. Die Anzahl der RBZ, 
sowie der Hämatokrit und der Hämoglobinspiegel waren im Vergleich zur Kontrolle 
signifikant erhöht. 
• Die Anzahl zirkulierender Thrombozyten in den ATG-Biotest und Merieux-ATG Gruppen 
war im Vergleich zu Fresenius ATG Gruppe und Kontrolle signifikant reduziert. 
• Die zytologische Untersuchung sowie das CIM zeigten signifikante Unterschiede hinsichtlich 
der Lymphzytotoxizität und der Depletion peripherer Lymphozyten in den ATG Gruppen im 
Vergleich zur Kontrolle.   
• Die histologische und immunhistochemische Analyse ergab eine reduzierte vaskuläre und 
perivaskuläre Infiltration, sowie eine Verminderung der Inflammation des muskulären 
Gewebes nach Behandlung mit ATG. 
• Die Expression von IL-4 war in den ATG Gruppen signifikant niedriger als in der Kontrolle. 
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7- APPENDIX: Tables 
The values of all the parameters studied distributed into groups are presented in this appendix. 
Values are shown as median + standard deviation. 
App 1.1.- Blood parameters 
App 1.1.1.-WBC 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 6,45 1,1705 6,45 0,8255 5 1,7742 9 2,7809 
0 3,92 0,7488 4,4 0,8280 3,3 1,3427 6,8 1,9602 
1 2,95 0,6124 3,3 0,7348 2,8 0,9571 5,9 3,9016 
5 2,9 0,7064 2,6 0,6129 2,4 1,2149 5,3 1,5093 
10 2,65 0,7160 2,3 0,5033 2,1 1,1870 3,55 1,9091 
15 2,55 0,9109 2,3 0,5219 2,1 0,9945 3,65 2,4748 
30 2,7 0,8354 1,9 0,4353 1,9 1,1840 1,5 1,9157 
45 2,2 1,0714 1,6 0,5468 1,6 1,2436 2,5 1,6802 
60 2,25 1,0342 2 0,7805 1,55 0,0707 2,6 1,2503 
 
Tab. 1: WBC-Short Ischemia: Number of WBC in PB. Values for every time point are expressed in number of cells x 
10³/µL 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 6,45 1,1846 6,1 0,7996 6,75 1,7075 9 2,8598 
0 4,15 0,5343 4,2 0,4615 4 1,1672 6,3 2,7624 
1 2,65 1,1519 3,2 0,5856 4,15 1,8266 5,1 2,21698 
5 2,7 0,9008 2,7 0,3193 3,45 1,4854 3,65 2,568 
10 2,65 0,7740 2,6 0,5727 3,2 1,3744 5,1 2,4724 
15 2,85 0,5873 2,3 0,3633 3,1 1,4974 4,05 1,2120 
30 2,6 0,6664 2,2 0,2607 2,55 1,0801 3,8 1,1344 
45 2,2 0,2810 2,1 0,1923 1,9 0,9609 2,8 0,70946 
60 2,25 0,7176 1,88 0,2178 2,3 0,5033 3,45 1,4849 
Tab. 2: WBC-Long Ischemia: Number of WBC in PB. Values for every time point are expressed in number of cells x 
10³/µL 
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App. 1.1.2.- RBC 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 5,095 0,3628 4,93 0,5676 4,79 0,4527 4,87 0,2885 
0 3,53 0,1943 3,4 0,2559 3,43 0,1109 3,47 0,4029 
1 3,375 0,3295 3,4 0,7274 3,52 0,4872 3,45 1,1664 
5 3,525 0,4471 3,35 0,6986 3,52 0,3440 3,33 0,7249 
10 3,615 0,5395 3,42 0,7135 3,5 0,202 3,34 0 
15 3,705 0,5149 3,33 0,8312 3,49 0,2135 3,38 0,0707 
30 3,875 0,5549 3,55 0,6945 3,44 0,5029 3,4 1,3741 
45 3,85 0,5889 3,92 0,5908 4,24 0,7442 3,3 0,4147 
60 4,26 0,8616 3,98 0,7166 3,285 0,6293 3,31 0,5200 
 
Tab. 3: RBC-Short Ischemia: Number of RBC in PB.  Values for every time point are expressed in number of cells x 
106/µL 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 4,705 0,4915 4,93 0,6565 5,185 0,455 4,315 0,4936 
0 3,355 0,2312 3,4 0,2306 3,475 0,2242 3,39 0,4445 
1 3,255 0,4305 3,49 0,2847 3,42 0,27702 3,46 0,7469 
5 3,315 0,5207 3,54 0,5558 3,36 0,2808 3,18 1,4345 
10 3,465 0,3605 3,59 0,2338 3,5 0,2542 2,9 1,0128 
15 3,495 0,2633 3,55 0,2977 3,615 0,3092 3,26 0,5899 
30 3,795 0,5576 3,91 0,4403 3,81 0,4011 3,38 0,8441 
45 4,165 0,5572 4,06 0,6333 4,19 0,5416 3,45 0,5676 
60 4,21 0,6321 4,02 0,7984 4,32 0,8083 3,12 0,791 
 
Tab. 4: RBC-Long Ischemia. Number of RBC in PB.  Values for every time point are expressed in number of cells x 
106/µL 
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App. 1.1.3. Platelets 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 220 63,13 210 59,688 192 44,679 274 43,482 
0 162,5 49,00 151 64,86 138 38,379 188 29,593 
1 119 52,770 146 19,093 128 31,100 140,5 33,826 
5 97,5 48,113 149 33,585 82 47,975 155 26,368 
10 108,5 52,151 145 36,404 118 34,095 157,5 0,7071 
15 88 52,415 137 26,333 108 28,342 154 8,4852 
30 86 50,974 132 64,605 93 24,513 140 52,252 
45 59 41,764 122 68,670 80 35,98 133 74,332 
60 64 29,518 117 93,811 115 38,37 119 12,342 
 
Tab. 5: Thrombocytes-Short Ischemia: Number of platelets in PB. Values for every time point are expressed in 
number of cells x 10³/µL 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 212 67,744 210 71,578 242 20,832 270,5 45,919 
0 160,5 52,512 151 75,457 154,5 51,990 176,5 41,126 
1 106 38,536 152 17,908 155 34,635 137,5 22,911 
5 91,5 36,492 148 41,644 156 30,309 134 71,092 
10 105,5 56,505 148 40,228 132 28,099 202 43,675 
15 69 58,585 140 52,276 127 23,614 136 22,278 
30 79 44,468 128 40,350 108,5 24,102 158 54,995 
45 73,5 44,159 128 39,268 98,5 30,490 147 54,921 
60 66,5 54,020 120 33,484 57 30,347 129,5 19,091 
 
Tab. 6: Thrombocytes-Long Ischemia: Number of thrombocytes in PB. Values for every time point are expressed in 
number of cells x 10³/µL 
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App. 1.1.4.Haematocrit 
 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 45,05 3,5139 45,5 5,0753 43,6 5,1250 38,6 2,6758 
0 30,8 1,4931 29,6 1,5126 31,5 1,1757 30,6 3,2957 
1 30,3 2,0465 29,6 6,9158 30,05 4,7053 30,8 10,140 
5 30,8 3,3028 30,3 6,4523 30,9 3,5888 29,8 6,3749 
10 31,2 4,2536 31,3 6,6725 31,3 1,9475 29,9 0,1414 
15 32,55 4,0083 30,5 7,5627 31,9 2,0958 30,25 0,6363 
30 34 3,8818 32,3 6,0717 30,3 4,3665 30,1 11,869 
45 33,8 4,2149 35,3 6,2353 34,55 6,061 29,7 2,783 
60 36,9 6,3443 35 5,9733 29,5 3,9597 29,9 4,050 
Tab. 7: HCT-Short Ischemia: haematocrit in % before and after dilution. 
 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 41,55 4,1379 43,5 5,4550 48,8 4,1931 38,75 3,4372 
0 30,4 1,5099 29,6 1,4024 30,95 1,6713 30,35 3,1784 
1 29,2 2,9794 30,9 2,6949 31,05 3,3491 27,05 6,1190 
5 29,15 3,8354 31 4,5025 31,35 1,7858 28,6 13,389 
10 30,35 2,3998 31,9 2,1349 32,2 1,7757 25,6 8,8017 
15 31,75 1,9449 31,1 3,0792 32,35 1,8779 29,15 5,4178 
30 35 4,1262 34,3 4,7072 33,55 3,2176 30,3 7,4503 
45 37,15 4,2589 36,8 7,4031 36,9 3,8974 29,2 5,2204 
60 38,5 5,5568 35,3 8,4690 38 6,3437 27,7 7,0710 
 
Tab. 8: HCT-Long Ischemia: haematocrit in % before and after dilution 
. 
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App. 1.1.5. Haemoglobin 
 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 15,05 1,2035 14,6 1,8087 14,1 2,023 13,9 0,8173 
0 10,6 0,8530 9,9 0,7184 10,3 0,7114 10,3 1,4060 
1 10,7 0,9057 10,3 1,9146 10,8 1,4138 10,6 3,9041 
5 10,95 1,0340 10,3 1,8680 10 1,3246 9,9 2,2576 
10 10,65 1,4945 10,8 1,9171 10,4 0,7967 10,35 0,6363 
15 11,15 1,3680 10,8 2,2825 11,1 1,0014 10,55 0,9192 
30 11,75 1,1400 11,3 1,9659 10,9 1,5565 10,1 4,2335 
45 11,7 1,1150 11,8 1,6118 11,7 2,1238 10,3 1,1590 
60 12,6 1,5793 12 2,1562 9,7 0,8485 10,5 1,3276 
 
Tab. 9: Hb-Short Ischemia: Amount of haemoglobin during the reperfusion after a SI period. 
 
 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 13,6 1,4232 14,6 1,9603 16,15 1,5649 12,8 1,1923 
0 10,45 0,7946 9,9 0,5449 10,6 0,7274 10 1,0264 
1 10,4 0,9818 10,1 0,7791 9,85 0,668 9,5 2,1173 
5 10,2 1,4030 10,4 1,2136 10,1 0,5 9,7 4,3431 
10 10,65 1,0192 10,8 0,7968 10,3 0,5477 9,3 2,9517 
15 11,2 1,0077 10,8 0,8700 10,45 0,6849 10,2 1,2419 
30 11,80 1,2668 11,5 1,1631 10,75 1,2027 9,9 1,9537 
45 12,8 1,6317 11,6 2,0005 11,5 1,285 9,9 0,7767 
60 13,3 2,1229 11,8 2,5449 12,1 2,0663 9,35 1,9091 
 
Tab. 10: Hb-Long Ischemia: Amount of haemoglobin during the reperfusion after a LI period. 
 
 
 
 134
App. 1.2.-Smears 
App. 1.2.1. Lymphocytes 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 30 13,69 28 12,12 54 14,76 39,5 20,14 
0 44 12,33 50 21,94 34 14,57 38 36,90 
1 40 8,51 28 16,02 42 14,24 50,5 41,71 
5 31 12,64 38 15,10 46 6,75 69 26,50 
10 44 19,49 29 25,37 48 9,94 58,5 53,03 
15 35 6,80 43 21,11 40 14,95 58,5 44,54 
30 31 7,14 30 18,41 40 9,21 94 32,33 
45 34 5,62 30 16,10 35 9,55 59 46,66 
60 29 7,27 32 20,17 24 5,50 88 26,15 
 
Tab. 11: Lymphocytes-Short Ischemia: Percentage of lymphocytes in PB smears after a period of SI (median and 
standard deviation are expressed in %). 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 32 13,64 24 8,67 35,5 11,57 39 16,25 
0 44 12,57 50 19,54 48 16,35 70 23,57 
1 50 22,58 36 21,33 25 18,09 32 20,42 
5 44 16,72 28 17,30 38 5,61 59 23,44 
10 30 18,00 28 16,04 32,5 11,09 63 26,65 
15 32 6,75 28 20,94 35,5 14,47 60,5 17,83 
30 37,00 9,17 30 19,21 29 11,75 69 17,38 
45 32 15,46 25 22,77 25,5 27,53 50 45,25 
60 26 17,31 24 23,55 21 9 52,5 36,06 
 
Tab. 12: Lymphocytes-Long Ischemia: Percentage of lymphocytes in PB smears after a period of LI ( median and 
standard deviation are expressed in %). 
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App.1.2.2 Neutrophils 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 58 13,33 61 8,99 44 12,73 55,5 18,73 
0 47 13,88 44 19,48 49 13,43 49 36,59 
1 55 10,18 45 14,07 51 14,85 45 41,01 
5 60 11,46 46 18,67 48 6,21 36,5 26,16 
10 49 15,57 53 23,71 50 10,46 37 49,49 
15 60 6,22 55 22,13 51 16,65 38,5 43,13 
30 63 5,99 59 16,58 58 5,47 29,5 38,89 
45 58 5,77 58 14,97 60 5,12 37,5 44,54 
60 62 10,46 48 18,21 69 4,04 4 24,82 
 
Tab. 13: Neutrophils-Short Ischemia: Percentage of neutrophils of the different study groups during the reperfusion 
after a SI period (median and standard deviation are expressed in %). 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 57 13,02 65 7,39 56,5 8,84 55 14,36 
0 47 13,26 44 17,60 43 11,16 26 20,55 
1 44 22,56 54 21,89 73,5 20,07 66 26,85 
5 54 16,87 58 29,35 53 10,37 40,5 22,41 
10 58 16,95 55 20,48 58,5 14,72 35 29,56 
15 58 14,43 50 24,26 60,5 13,04 33,5 21,07 
30 56 9,77 40 25,40 62 16,58 16 20,29 
45 60 17,17 32 22,42 62 22,41 41,5 50,20 
60 66 18,87 40 25,54 70 11,01 37,5 43,13 
 
Tab. 14: Neutrophils-Long Ischemia: Percentage of neutrophils of the different study groups during the reperfusion 
after a LI period (median and standard deviation are expressed in %). 
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App. 1.2.3. Monocytes. 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 8 4,02 9 3,77 6 4,19 5 2,58 
0 8 2,34 8 4,15 6 1,97 8 2,88 
1 6 3,73 4 1,60 3 2,96 4,5 0,70 
5 5 3,25 5 3,03 3 3,35 4 5,29 
10 7 3,90 3 4,18 6 5,61 4,5 3,53 
15 5 2,94 5 2,26 1,5 6,28 3 1,41 
30 4 3,14 7 2,54 2 3,20 5 1 
45 5 4,54 6 2,50 2 4,38 3,5 2,12 
60 5 3,71 6 3,09 4 2,51 7 3,21 
 
Tab. 15: Monocytes; Short Ischemia: Percentage of monocytes during the reperfusion after a SI time (median and 
standard deviation are expressed in %). 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 8 4,02 10 3,43 6 4,19 6 2 
0 7 2,85 8 4,43 7,5 2,62 8 4,50 
1 4 3,54 4 3,19 4 3,30 3 4,35 
5 4 3,45 5 2,30 7 1,5 4 4,52 
10 8 3,04 3 2,34 6,5 2,08 4 3,05 
15 6 3,31 3 3,27 4,5 1,41 7 3,46 
30 5 1,51 4 1,94 7,5 6,70 10 4,04 
45 6 2,22 5 2,54 5 5,59 7,5 3,53 
60 6 3,76 6 3,56 8 3,51 8,5 6,36 
 
Tab. 16: Monocytes-Long Ischemia: Percentage of monocytes during the reperfusion after a LI time (median and 
standard deviation are expressed in %). 
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App. 1.3.-CIM 
App. 1.3.1. Lymphocytes 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 73 14,19 69 4,25 56,5 13,21 32 0 
0 64 20,83 62 21,28 62 14,18 50 16,97 
1 39 17,33 65 14,86 36 26,49 64 7,07 
5 30 6,04 39 13,16 42 13,59 85 28,21 
10 32 13,77 29 12,53 36 17,68 22 0 
15 23 9,80 30 10,62 34 19,79 11 0 
30 26 6,28 28 13,56 33,5 9,89 57 55,15 
45 27,5 7,32 42 23,22 27 14,24 29 0 
60 22 6,01 36,5 16,09 45 17,03 62 48,08 
 
Tab. 17: Lymphocytes-Short Ischemia: Percentage of lymphocytes with CIM after a SI period. (median and standard 
deviation are expressed in %). 
 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 72 7,99 69 5,01 63 8,42 62 0 
0 54 24,59 66 25,80 66 10,50 63 1,41 
1 41 10,86 39 19,25 41 21,31 29 0 
5 39,5 11,78 41 12,32 35,5 10,42 78 22,62 
10 41 14,95 36 17,22 37 7,54 68,5 34,64 
15 32,5 15,58 33 13,88 29 10,78 61 32,52 
30 28,00 11,43 34 13,44 33 13,50 58,5 48,79 
45 38,5 15,31 41,5 17,68 23,5 5,73 49 46,66 
 24 14,82 25 12,50 24 14,50 16 0 
 
Tab. 18: Lymphocytes-Long Ischemia: Percentage of lymphocytes with CIM after a LI period. (median and standard 
deviation are expressed in %). 
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1.3.2. Neutrophils 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 0 16,01 0 0 1,5 3,50 60 0 
0 8 23,72 11 27,68 21,5 21,23 26,5 31,81 
1 49 18,34 27 22,26 60,5 28,12 24 0 
5 64 7,69 50 19,67 56 23,51 26 36,76 
10 62 12,52 62 17,73 59 19,62 69 0 
15 68 10,12 60 14,78 65 20,49 84 0 
30 69 8,44 62 16,31 63 10,03 35,5 50,20 
45 63,5 10,47 44 20,13 69,5 13,83 66 0 
60 74 5,40 59,5 16,49 53 33,04 33 46,66 
 
Tab. 19: Neutrophils-Short Ischemia: % of neutrophils after a period of SI. (median and standard deviation are 
expressed in %). 
 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 0 9,77 0 0 0 4,5 21 24,04 
0 22 28,96 11 32,76 15 13,01 45 12,72 
1 46 11,97 42 25,71 33 19,73 28 0 
5 52,5 10,69 52 15,75 56 32,53 22,5 23,33 
10 55 11,64 54 15,05 59 6,94 30 32,52 
15 62 13,27 55 15,11 57 11,06 42 41,01 
30 63,5 14,75 54 12,70 62 8,62 42 49,49 
45 57 17,70 42,5 16,89 67,5 3,51 46 45,25 
60 68 15,70 59 16,56 74 19,54   
 
Tab. 21: Neutrophils-Long Ischemia: % of neutrophils after a period of LI. (median and standard deviation are 
expressed in %). 
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App.1.3.3. Monocytes 
 
 BSI FSI MSI CSI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 23 10,03 29 4,68 42,5 13,61 8 0 
0 18 13,26 20 15,22 12 10,27 23,5 14,84 
1 7 3,74 9 8,38 4,5 3,61 14 0 
5 5 4,816 9 6,50 3 5,472 10 7,07 
10 3 4,70 5 6,06 1,5 4,35 7 0 
15 4 4,03 4 7,38 2,5 1,36 5 0 
30 4 5,23 6 3,46 1 0,81 6 2,82 
45 5 4,05 5 5,43 1 1,5 4 0 
60 3 1,83 4 2,33 2 19,92 4 0 
Tab. 21: Monocytes -Short Ischemia: % of monocytes (CIM) after a SI period (median and standard deviation are 
expressed in %). 
 
 BLI FLI MLI CLI 
Time Median Sta.De. Median Sta.De. Median Sta.De. Median Sta.De. 
-30 28 12,98 28 5,06 34 10,66 0 0 
0 15 10,77 18 13,74 27 12,66 17 24,04 
1 9 8,39 18 10,22 7,5 2,16 8,5 12,02 
5 3 3,02 7 5,49 3 4,19 5 7,071 
10 6,5 2,87 6 2,44 6 4,12 8,5 12,02 
15 4,5 2,67 7 3,36 2 4,61 4 5,65 
30 4 2,60 3 5,41 3 1 2,5 3,53 
45 4 3,50 6 4,85 4 5,47 2,5 3,53 
60 3 4,50 1 8,38 7 5,50 3 0 
Tab. 22: Monocytes-Long Ischemia: % of monocytes (CIM) after a LI period (median and standard deviation are 
expressed in %). 
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App. 1.4: Histological results 
 
CSI FSI BSI MSI CLI FLI BLI MLI  
mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D mean St. D 
Muscle 
Damage 
 
2,6 
 
0,51 0,9 0,73 
 
1,1 0,73 1,2 0,63 2,8 0,42 1 0,66 1,6 0,69 1,4 0,51
Connect. 
Infiltration 
 
2,5 
 
0,52 1,1 0,31 
 
1,2 0,42 1,3 0,48 2,3 0,67 1,3 0,48 1,4 0,51 1,3 0,48
Vascular 
Infiltration 
 
2,3 
 
0,48 1,1 0,31 
 
1,3 0,48 1,4 0,51 2,4 0,69 1,5 0,52 1,5 0,52 1,3 0,48
Perivasc. 
Infiltration 
 
2,3 
 
0,67 1,2 0,42 
 
1,3 0,48 1,3 0,48 2,3 0,67 1,2 0,42 1,4 0,51 1,5 0,52
Muscular 
Infiltration 
 
2,4 
 
0,69 0,5 0,52 
 
0,4 0,51 0,4 0,51 2,7 0,48 0,4 0,51 0,6 0,51 0,9 0,79
Presence 
Fibrin 
 
1,9 
 
0,56 0,3 0,48 
 
1,2 0,63 0,8 0,63 2,2 0,63 0,8 0,63 1,3 0,67 1,1 0,56
 
Tab. 23: Values obtained after semi-quantitative analysis of the histological and immunohistochemical sections. 
Results expressed as mean + standard deviation 
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